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Abstract 
      Cancer cells are known to display increased glucose uptake and consumption. The 
glucose transporter (GLUT) proteins facilitate glucose uptake, however, their exact role 
in cancer metabolism remains unclear. The present study examined mRNA and protein 
expression of GLUT1, GLUT3, GLUT4 and GLUT12 in lung, breast and prostate cancer 
cells and corresponding noncancerous cells. Additionally, GLUT expression was 
determined in tumours from mice xenografted with human cancer cells. Differences in 
the mRNA and protein expression of GLUTs were found between cancerous and 
corresponding noncancerous cells. These findings demonstrate abundant expression of 
GLUT1 in cancer and highlight the importance of GLUT3 as it was expressed in several 
cancer cells and tumours. GLUT expression patterns in vitro were supported by the in 
vivo findings. The study of GLUT protein expression in cancer is important for 
understanding cancer metabolism and may lead to identification of biomarkers of cancer 
progression and development of target therapies.  
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CHAPTER 1: LITERATURE REVIEW 
1.1 Cancer 
 
     Unlike healthy cells, cancer cells share specific properties enabling malignant 
growth
1
. One of the most fundamental characteristics of cancer cells is their uncontrolled 
proliferative capacity, resulting from oncogenic mutations that deregulate signals 
controlling the cell growth-and-division cycle
1
. In order to sustain enhanced proliferation, 
cancer cells have increased requirements for sugars, fatty acids and amino acids. These 
nutrients provide energy and serve as the building blocks for macromolecules
2
. Although 
cancer cells display alterations in the metabolism of all classes of macromolecules, the 
role of carbohydrate metabolism in cancer has received attention in recent years because 
cancer cells are particularly dependent on glucose metabolism for energy production.   
1.2 Glucose Metabolism in Cancer 
     Metabolic changes are a common feature of cancer cells. Although the glycolytic 
pathway is ubiquitous in the body, its role can differ between healthy and cancerous cells. 
The following sections describe how glucose is metabolized to provide energy and the 
modifications that may occur to this process in cancer.  
1.2.1 Glycolysis 
     The ATP required for cellular processes is generated primarily through two pathways: 
glycolysis and the citric acid cycle. During glycolysis, one molecule of glucose is 
metabolized through a series of reactions and split into two pyruvate molecules. The 
reactions and enzymes of glycolysis can be seen in Figure 1. In the first step, glucose 
becomes phosphorylated to glucose-6-phosphate in an endergonic reaction requiring 
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Figure 1. The metabolic pathway of glycolysis. Each glucose molecule that is metabolized 
through this process produces a net energy yield of 2 ATP. Although various cells of the 
body use this pathway, many types of cancers show a greater dependence on this pathway to 
provide energy
3
.  
 
energy from ATP. Next, glucose-6-phosphate is isomerized to fructose-6-phosphate. In 
the third step of glycolysis, phosphofructokinase catalyzes the transfer of ATP to 
fructose-6-phosphate to form fructose-1,6-bisphosphate. This reaction is 
thermodynamically favorable and it is known as a committed step because fructose-1,6-
biphosphate can only react in glycolysis, unlike glucose-6-phosphate which can be 
shunted to other pathways. Fructose-1,6-biphosphate is then split into two 3-carbon units 
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that are oxidized to pyruvate, producing a net energy yield from each glucose molecule of 
two ATP and two NADH
3
.  
 
1.2.2 The Citric Acid Cycle 
     If adequate oxygen is present, pyruvate continues into the citric acid cycle. However, 
under conditions of limited oxygen, pyruvate becomes converted into lactate by the 
enzyme lactate dehydrogenase in a process known as anaerobic glycolysis. One NAD
+
 is 
regenerated in the process of reducing pyruvate and is re-used in the glycolytic pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The fate of pyruvate. In healthy cells, pyruvate is converted to lactate under 
anaerobic conditions. If oxygen is present, pyruvate is converted to Acetyl-CoA and 
continues into the citric acid cycle. Cancer cells may display conversion of pyruvate to 
lactate even in the presence of oxygen
3
. 
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so that ATP production can continue to occur in the absence of oxygen.  
     Under aerobic conditions, pyruvate is transported into the mitochondria and converted 
to acetyl Coenzyme A (CoA) by the pyruvate dehydrogenase complex. The two-carbon 
acyl unit of acetyl CoA enters the citric acid cycle by combining with oxaloacetate to 
form citrate. The series of reactions of the citric acid cycle can be seen in Figure 2. 
Citrate is further oxidized to release carbon dioxide and produce NADH from NAD
+
 with 
each oxidative decarboxylation. The cycle is completed when an oxaloacetate molecule is 
regenerated. For each molecule of glucose oxidized, two full turns of the citric acid cycle 
are completed (one per pyruvate), yielding a total of 6 NADH, 2 FADH2 and 2 GTP
3
.   
 
1.2.3 Oxidative Phosphorylation 
 
     Oxidative phosphorylation takes places across the inner mitochondrial membrane. It 
uses oxidation of the high energy electrons from NADH and FADH2, produced in 
glycolysis and the citric acid cycle, to pump protons out of the mitochondrial matrix and 
into the inter membrane space. The electron transport chain is performed by electron 
carrier protein complexes embedded in the inner mitochondrial membrane which receive 
electrons in sequence from NADH dehydrogenase → ubiquinone → cytochrome C 
reductase → cytochrome C → cytochrome C oxidase (Figure 3). Oxygen acts as the final 
electron acceptor combining with protons to form water. As the electrons are passed from 
protein to protein, energy is used to pump H+ out of the matrix across the inner 
mitochondrial membrane into the intermembrane space. This creates a proton gradient  
which drives protons to pass back into the matrix through the ATP synthase channel and  
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produces ATP from ADP and PO4
2-
 in the process. The net yield of ATP produced from 
one glucose molecule catabolized through the aforementioned aerobic pathways in 
eukaryotes is approximately 30, depending on the number of protons available for ATP 
synthesis.  This represents a significant increase in energy yield compared to the 2 ATP 
produced in the anaerobic conversion of glucose to lactate.  
 
 1.2.4 The Warburg Effect  
     In 1920, the renowned biochemist Otto Warburg observed that human and animal 
tumours rely on the conversion of glucose into lactate for energy production instead of 
mitochondrial oxidation, even in the presence of oxygen
4
. His observation is supported 
 
 
 
 
 
 
 
 
 
 
Figure 3. The electron transport chain. Electron carriers of the electron transport chain are found in the inner 
mitochondrial membrane. Healthy cells use these carriers to oxidize high energy electrons from NADH and 
FADH2, pumping protons out of the mitochondrial matrix in the process and creating a proton gradient that is 
used to phosphorylate ADP to ATP
3
.  
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by the elevated levels of lactate dehydrogenase that have been found in various cancers
5
. 
The preferred conversion of glucose to lactate for energy production in the presence of 
oxygen (referred to in this text as aerobic glycolysis) in tumour cells became known as 
the “Warburg Effect”.  
     There has been great interest in understanding why tumour cells, with increased 
metabolic needs, use such an inefficient pathway to derive energy from glucose. Initially, 
it was suggested that tumour cells use aerobic glycolysis because of mitochondrial 
defects preventing ATP production by oxidative phosphorylation
4
. However, this 
hypothesis was countered by studies showing that aerobic glycolysis is reversible and in 
most cases there is no permanent mitochondrial damage in cancer cells. This was 
demonstrated using short hairpin RNA-mediated knockdown of lactate dehydrogenase in 
mammary tumour cells, where inhibition of lactate production stimulated mitochondrial 
respiration in these cells
6
. In another study, dichloroacetate, a small molecule inhibitor of 
pyruvate dehydrogenase kinase, was used to activate pyruvate dehydrogenase and induce 
cancer cells to oxidize pyruvate in the citric acid cycle
7
. Although the breast cancer, non-
small-cell lung cancer, and glioblastoma cells used were able to perform mitochondria-
based glucose oxidation after this induction, apoptosis was increased. This indicates that 
aerobic glycolysis is also vital for cancer cell survival. Furthermore, there is some 
evidence to suggest that a degree of mitochondrial metabolism is needed for ROS 
production in tumourigenesis and growth
8,9
. 
     The current theory behind the Warburg effect explains that tumour cells switch to 
aerobic glycolysis in order to produce intermediates needed for cell growth and 
division
10
. Healthy cells and cancer cells both use glucose to produce ATP and to 
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generate metabolites required for synthesis of amino acids, fatty acids and nucleotides. 
Although some ATP is needed in the reactions that produce macromolecules, in 
proliferating cancer cells there is a greater demand to covert glucose to macromolecular 
precursors than to produce ATP through oxidative phosphorylation by metabolizing 
glucose to CO2 and H20
10
. Glucose can provide six carbons for macromolecule synthesis 
or be shunted through the pentose phosphate pathway to generate NADPH needed for the 
synthesis of fatty-acids and nucleotides
10
. Although cancer cells do not use the most 
efficient pathway to produce ATP, with a constant supply of glucose and nutrients in the 
blood, aerobic glycolysis appears to represent a good survival strategy
10
.  
     Furthermore, acidification of the local environment due to excess lactate secretion of 
tumour cells has been shown to promote invasion and enhance cell motility. Lactate was 
shown to stimulate fibroblast expression of hyaluronan, a polysaccharide found in the 
extracellular matrix, and its receptor CD44
11
. The effect of hyaluronan is to separate cells 
by diminishing contact between them, this creates an environment that allows the spread 
of cancer cells
11
. Lactate also has direct effects on cell motility, as shown by its ability to 
induce expression of Transforming growth factor-beta2 (TGF- 2), a key regulator of 
invasion, in glioma cells
12
.  
 
1.3 Glucose Transporter Proteins  
     Due to its hydrophilic nature, glucose requires specific carrier proteins to cross the 
plasma membrane of cells. Glucose uptake across the plasma membrane is the rate-
limiting step for glucose consumption in healthy cells and tumours. There are two  
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 families of membrane-associated carriers that mediate the transport of glucose into the 
cell: the facilitative glucose transporter (GLUT) proteins and the sodium-coupled glucose  
 cotransporter (SGLT) proteins
13
. 
      The SGLT family consists of 12 members from the human genome that function as 
cotransporters for sugars, anions, vitamins, and short-chain fatty acids
14
. These proteins 
are expressed in the epithelial cells of the small intestine and kidney, as well as the brain, 
muscle and thyroid gland
14
. Three members of the family have a role in sugar transport, 
these are the sodium-dependent glucose cotransporters (SGLT1 and SGLT2), and SGLT3 
which is believed to act as a glucose sensor
14
. SGLT proteins transport glucose into the 
cell against its concentration gradient using energy provided by the sodium gradient 
across the cell membrane
14
.  
     Fourteen members of the GLUT protein family have been identified in humans
15
. 
These transporters show a high degree of homology and share the following common 
features: (1) GLUTs are predicted to have a tertiary structure of twelve transmembrane 
domains with intracellular amino- and carboxyl-ends )16 (Figure 4): The transmembrane 
domains are numbered from N-terminus to C-terminus with a large intracellular loop 
existing between transmembrane domains 6 and 716. (2) The presence of seven conserved 
glycine residues within the transmembrane helices: These residues are regarded as being 
essential for facilitative transporter function, this has been confirmed using site-directed 
mutagenesis where glycine residues at position 75, 76 and 79 were found to be necessary 
for transport activity of GLUT1 from Xenopus oocytes
17
. (3) Several basic and acidic 
residues at the intracellular surface of the proteins: The significance of some of these  
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Figure 4. Schematic model of the structure of Class I and II and Class III members of the GLUT 
family. Twelve hydrophobic transmembrane domains are numbered and connected by hydrophilic 
loops. The characteristic N-glycosylation sites found between transmembrane domains 1 and 2 in 
Class I and II, and between transmembrane domains 9 and 10 in Class III can be seen. The seven 
conserved glycine residues and the conserved tryptophan and tyrosine residues are shown 
individually
16,24
. G, glycine; W, tryptophan; Y, tyrosine; L1-11, loops 1-11. 
 
residues has been examined using mutational analysis; arginine and glutamate residues 
were found to be essential for the conformation of GLUT4 in COS-7 cells
18
. The amino  
acid motif R-X-G-R-R was also found to provide the proper membrane topology of 
GLUTs in Xenopus oocytes
19
. (4) Conserved tryptophan residues at helices 6 and 11: The  
 tryptophan in helix 11 of GLUT1 has been shown to be essential for both transport 
activity and the binding of the glucose transport inhibitors cytochalasin B and 
Investigation of the Expression of Glucose Transporter Proteins in Human Cancer Cells 10 
forskolin
20,21
. (5) Conserved tyrosine residues in helices 4 and 7: It has been 
demonstrated that these residues are important for the transport activity of GLUT1 and 
GLUT4
22,23
.  
  
     The nomenclature of GLUT1-5 was based on the chronological order of cloning of 
their genes. Sequence information provided by various genome projects led to the 
identification of the novel sugar transporters and a new GLUT nomenclature was devised 
based on sequence homology
24
. The GLUTs can be grouped into three classes (Figure 5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Dendogram of multiple alignment of the GLUT family. Branch lengths reflect 
the degree of difference between sequences. Adapted from Joost et. al (2001)
24
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which differ in the position of a predicted long extracellular loop. In Class I (GLUT1, 
GLUT2, GLUT3, GLUT4) and II (GLUT5, GLUT7, GLUT9, GLUT11) proteins, this 
loop containing an N-linked glycosylation site is found between transmembrane domains 
1 and 2. In Class III proteins, the extracellular loop with sites of N-linked glycosylation is 
located between transmembrane domains 9 and 10 (Figure 4)24. Glycosylation at this site 
has been shown to increase the efficiency of glucose transport
25
. An additional difference 
between classes is the presence of an internalization signal possessed by Class III 
transporters that localizes them intracellularly under steady state conditions
26
. This 
internalization signal has been identified as the motif YSRI for GLUT10 and dileucine 
for the remaining Class III transporters
26
. Although GLUT4 possesses internalization 
signals it is classified as a Class I transporter (See GLUT4 Structure/Affinity). Residues 
that are specific to the Class I transporters include a glutamine in helix 5 and the STSIF-
motif in the extracellular loop 7
27,28
. Class II transporters lack a tryptophan following the 
conserved GPXXXP motif in helix 10 that is found in the other GLUT transporters. In 
GLUT1 this tryptophan was found to be important for binding of the ligands cytochalasin 
B and forskolin, but did not influence transport activity
20,21
.  
     Unlike SGLT proteins which require energy to transport glucose, GLUT transporters 
move sugars via diffusion
29
. The transport of glucose by these proteins can be described 
as an alternating conformer model in which the transporter has mutually exclusive 
binding sites for glucose on its intracellular and extracellular side
15
. Binding of glucose to 
one of the sites triggers a change causing the transporter to switch to the other 
conformation and transport glucose across the plasma membrane during the process
15
.  
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Table 1. Summary of the properties of the GLUT family  
Protein Major 
Isoform (aa) 
Molecular 
Weight (kDa) 
Substrates Major Sites of 
Expression  
GLUT1 492 54  Glucose ( Km 3 mM)  
Galactose ( Km  17 mM) 
Mannose ( Km 20 mM) 
Glucosamine ( Km 2.5 mM) 
DHA ( Km 1.1 mM)  
Ubiquitous distribution 
GLUT2 524 55 Glucose ( Km  17 mM)  
Galactose ( Km 92 mM) 
Mannose ( Km 125 mM) 
Glucosamine ( Km 0.8 mM) 
Fructose ( Km  76 mM) 
Kidney, small intestine, 
liver, pancreas 
GLUT3 496 45 2-deoxy-D-glucose ( Km  1.4 
mM)  
Galactose ( Km 8.5 mM) 
Mannose  
Maltose  
Xylose  
DHA 
Brain, nerves 
GLUT4 509 55 Glucose ( Km  5 mM)  
DHA ( Km 0.98 mM) 
Glucosamine ( Km 0.8 mM) 
Muscle, fat, heart 
GLUT5 501 55 Fructose ( Km  6 mM) 
 
Intestine, kidney, testis 
GLUT6 507 46 Glucose Spleen, brain, leukocytes 
GLUT7 524 53 Glucose ( Km  0.3 mM)  
Fructose ( Km 0.2 mM) 
 
Small intestine, colon, 
testis, prostate 
GLUT8 477 51.5 Glucose ( Km  2 mM)  
 
Testis, brain, adrenal 
gland, liver, spleen, fat, 
lung 
GLUT9 511/540 66/46 Glucose ( Km  0.61 mM)  
Fructose ( Km  0.42 mM) 
Urate ( Km  0.9 mM) 
Liver, kidney, placenta 
GLUT10 541 57 2-deoxy-D-glucose ( Km  0.3 
mM)  
Glucose 
Galactose 
Heart, lung, brain, liver, 
muscle, pancreas, 
placenta, kidney 
GLUT11 496 54 Glucose ( Km 0.16 mM)  
Fructose ( Km 0.16 mM) 
 
Heart, muscle, kidney, 
placenta, fat, kidney, 
pancreas 
GLUT12 617 67 Glucose Muscle, heart, fat, small 
intestine, prostate, 
placenta 
GLUT14 497/520 N/A N/A Testis 
HMIT 618/629 69 Myoinositol ( Km  0.1 mM)  Brain 
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Glucose transport may be blocked by competitive inhibition by other sugars or 
metabolites at the extracellular or cytosolic sugar binding sites.        
     The GLUT proteins exhibit different substrate specificities, regulation and tissue 
expression
29
. The following summarizes the available data about the GLUT transporters 
with specific focus on Class I transporters GLUT1, GLUT3, GLUT4 and the Class III 
transporter GLUT12.  
Class I 
1.3.1 GLUT1 
Structure 
     GLUT1 is the first discovered and best characterized facilitative glucose transporter. 
In humans, it consists of a protein sequence of 492 amino acids with a molecular weight 
of approximately 54 kDa
30
. The N-linked glycosylation site found in loop 1 is the most 
divergent region among species
30
. Overall, GLUT1 is a highly conserved isoform and 
exhibits 74-98% sequence identity among fish, chickens, humans, bovines, rats and 
mice
30
.  
     Despite intensive study, a crystal structure of GLUT1 has not been determined
31
. 
GLUT1 is thought to exist as homodimers or homotetramers in human erythrocytes 
where its conversion between the two forms is dependent on the redox state
32
. In a 
reducing environment, tetrameric GLUTl was found to dissociate into GLUT1 dimers
32
.  
Affinity 
     In Xenopus oocytes, GLUT1 has been shown to transport glucose with a Km of 
approximately 3 mM
33
. GLUT1 transports mainly glucose but can also transport 
galactose (Km 17 mM), mannose (Km 20 mM) and glucosamine (Km 2.5 mM)
33,34
. In 
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addition, it has been shown to transport the oxidized form of vitamin C, dehydroascorbic 
acid with a Km of 1.1 mM when using a Xenopus oocyte expression system
35
.  
Expression 
     GLUT1 is responsible for basal glucose uptake, therefore, is expressed in virtually all 
tissues under normal conditions
29. It is referred to as the “Erythrocyte-Type Glucose 
Transporter” due to its high expression in erythrocyte cell membranes where it composes 
3-5% of total membrane protein
30
. High levels of GLUT1 can also be found in 
endothelial and epithelial cells from blood-tissue barriers in the brain, eye, peripheral 
nerve, placenta and lactating mammary gland
36,37
.    
1.3.2 GLUT3 
Structure/Affinity 
     GLUT3 consists of a protein sequence of 496 amino acids with a molecular weight of 
approximately 45 kDa
30
. GLUT3 transports glucose with a high affinity (Km 1.4 mM for 
2-deoxy-D-glucose)
46
. GLUT3 is also capable of transporting galactose (Km 8.5), 
dehydroascorbic acid (Km 8.5) and mannose and xylose, for which the Km values have 
not been described
15,35
. In primary cultured cerebellar granule neurons it was 
demonstrated that GLUT3 has a higher catalytic center activity than GLUT1, 853 sec
-1
 
versus 123 sec
-1
, suggesting it is the more active transporter
38
.  
Expression 
     GLUT3 mRNA is ubiquitously expressed in human tissues, however, its protein is 
primarily found in the brain and testis
15
. The calculated turnover rate of GLUT3 
compared to GLUT1 means that cells expressing GLUT3 have the capacity to transport 
seven times more glucose assuming an equal number of transporters on the plasma 
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membrane
38
. This high transport capacity and affinity of GLUT3 for glucose are 
especially important because GLUT3 introduces glucose into neurons from the 
interneuronal space where its concentration is low
29
. GLUT3 is highly expressed in the 
membrane of human testis as well as the spermatozoa
39
.    
1.3.3 GLUT4 
Structure/Affinity 
     GLUT4 consists of a protein sequence of 509 amino acids with a molecular weight of 
approximately 55 kDa
30
. This protein is highly conserved in humans, bovines, rats and 
mice with 91-96% sequence similarity
30
. GLUT4 has a Km for glucose of approximately 5 
mM
30
. It can also transport dehydroascorbic acid (Km 0.98 mM) and glucosamine (Km 3.9 
mM)
35,40
.  
Expression 
     GLUT4 is highly expressed in the insulin sensitive tissues including brown and white 
adipose tissue and skeletal and cardiac muscle
15
. It is the major glucose transporter in 
these tissues and thus plays a critical role in whole body glucose homeostasis.    
Class III 
     The Class III facilitative glucose transporters are recently discovered and include 
GLUT6, GLUT8, GLUT10, GLUT12 and the H
+
/myo-inositol co-transporter HMIT. 
They are not as well characterized as the other glucose transporters. These transporters 
are expressed in humans and were identified as a consequence of sequencing the human 
genome. In general, little is known about their functions and substrates. 
1.3.4 GLUT12 
Structure/Affinity 
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     GLUT12 consists of a protein sequence of 617 amino acids with a molecular weight 
of approximately 67 kDa
30
. GLUT12 shows glucose transport activity but the affinity of 
the transporter for glucose remains unknown
26
. This glucose transport can be 
competitively inhibited by fructose, galactose and 2-DG
26
.   
Expression 
     GLUT12 expression is found in insulin-sensitive tissue including skeletal muscle, 
cardiac muscle and fat as well as the small intestine, prostate and placenta
41
. It was 
originally cloned in MCF-7 breast cancer cells. The expression of GLUT12 has been 
found to be stronger in ductal cell carcinoma in situ cells than in benign ducts of breast 
cancer tissues
42
. This suggests that although GLUT12 does not play a major role in 
glucose transport to healthy breast tissue, it becomes significant in providing sugars to 
malignant cells.  
 
1.4 Molecular Mechanisms Driving the Warburg Effect  
1.4.1 The PI3K-Akt Signaling Pathway  
    The phosphatidylinositol 3-kinases (PI3Ks) are a family of lipid kinases responsible 
for regulating growth and survival processes
43
. Three classes of PI3Ks exist based on 
structure and substrate specificity
44
. Class I enzymes consist of heterodimers that 
phosphorylate phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2), Class II enzymes 
consist of a single catalytic subunit and preferentially use phosphatidylinositol or 
phosphatidylinositol-4-phosphate as substrates and Class III enzymes consist of a single 
catalytic subunit that only produces phosphatidylinositol-3-phosphate
44
.  
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     Class I enzymes are further divided into Class IA PI3Ks which can be activated by 
receptor tyrosine kinases, G protein coupled receptors (GPCRs) and oncogenes while 
Class IB PI3Ks are activated exclusively by GPCRs
44
.     
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. The PI3K signaling pathway. The family of lipid kinases termed PI3Ks has been 
found to have a key role in regulating cell survival and proliferation. Mutations that 
constitutively activate this pathway are common in cancer
43-45
.  
 
     As seen in Figure 6, the Class IA PI3K pathway is initiated by a ligand binding to a 
cell surface receptor that recruits PI3K to the membrane by direct interaction of its Src 
homology domain 2 (SH2) domain, located within the p85 regulatory subunit, with  
tyrosine phosphate motifs on the activated receptor or adaptor proteins
44
. This removes 
inhibition of the p110 catalytic subunit which is then free to phosphorylate the membrane 
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phospholipids phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) to generate 
phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P3)
44
. PIP3 serves as a plasma 
membrane docking site for proteins with pleckstrin-homology (PH) domains, including 
Akt, an oncoprotein that is frequently dysregulated in cancer
43
. Akt is a 57 kDa protein 
that exists in three isoforms (Akt1, Akt2, Akt3) all sharing a PH domain, a central kinase 
domain and a carboxy terminal regulatory domain
44
. In response to docking at the plasma  
membrane, Akt undergoes a conformational change exposing two amino-acid residues 
that must by phosphorylated for its full activation
44
. The first, Thr-308, is phosphorylated 
by the protein 3’- phosphoinositide- dependent kinase-1 (PDK-1) which is also recruited 
to the membrane by PIP3.  Ser-473 is the second amino-acid residue which is 
phosphorylated by the mammalian target of rapamycin complex 2 (mTORC2).   
     Mutations of the Class IA PI3Ks have been shown to occur frequently in cancer
45
. A 
common mutation occurs in the PIK3CA gene, encoding for the catalytic subunit p110 , 
which leads to the pathway being constitutively activated
45
. In addition, loss of the 
important tumour suppressor phosphatase and tensin homolog (PTEN) can result in 
uncontrolled PI3K signaling leading to cancer. This phosphatase is responsible for 
removing a phosphate group from PIP3 converting it back to PIP2 and thus preventing 
downstream signaling of the pathway.   
     Evidence indicates that Akt is involved in the Warburg Effect (Figure 7). Akt has 
been shown to promote glycolysis through a number of mechanisms. In both skeletal 
muscle and cancer cells, Akt has been shown to induce the expression of the glucose 
transporter (GLUT) proteins GLUT1 and GLUT3 and the translocation of GLUT4 to the 
plasma membrane, thereby allowing glucose to enter the cell
46-48
. Akt also  
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phosphorylates hexokinase, the enzyme of the first- and rate-limiting step in glycolysis
49
. 
Finally, in bovine heart tissue Akt has been shown to directly phosphorylate and activate 
phosphofructokinase-2 which catalyzes the formation of the product fructose-2,6- 
biphosphate (Fru-1,6-P2)
50
. Fru-1,6-P2 is responsible for allosterically activating the most 
important regulatory enzyme of glycolysis, phosphofructokinase-1 (PFK-1). The 
ability of Akt to increase glycolysis without increasing oxidative phosphorylation 
suggests it may play an important role in contributing to the Warburg Effect.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Akt in the Warburg Effect. Activation of the protein Akt through the PI3K pathway has 
been shown to promote glucose uptake and glycolysis in healthy and cancerous cells. This is 
achieved by inducing the expression and translocation of GLUT proteins
46-48
, activating the enzyme 
hexokinase
49
 and promoting the activation of PFK-1
50
. Because this pathway is frequently 
deregulated in cancer it is suggested these actions contribute to the Warburg Effect.   
Investigation of the Expression of Glucose Transporter Proteins in Human Cancer Cells 20 
1.4.2 HIF-1 
     The mammalian target of rapamycin (mTOR) is a 250 kDa serine/threonine kinase 
that controls growth and regulates protein synthesis
2
. It exists in two distinct complexes 
termed mTORC1 and mTORC2
51
 (Figure 8). The mTORC1 complex consists of the 
mTOR catalytic subunit, regulatory associated protein of mTOR (raptor), proline-rich 
Akt substrate (PRAS40) and the protein mLST8. mTORC2 is composed of mTOR, 
rapamycin insensitive companion of mTOR (rictor), mammalian stress-activated protein 
kinase interacting protein 1 (MSIN1) and mLST8. Akt has been shown to activate the 
mTOR pathway by acting on two substrates
51
. Activated Akt phosphorylates the tuberous 
sclerosis complex (TSC) 2 and relieves the inhibitory effects of the tuberous sclerosis 
complex (TSC1/TSC2) upon the small G protein Rheb. When in the GTP-bound form, 
Rheb strongly activates mTORC1. Akt can also activate mTOR by phosphorylating 
PRAS40 to attenuate its inhibitory effects on mTORC1. This complex is responsible for  
regulating translation initiation and ribosome biogenesis through its downstream 
targets
51
.  
     The hypoxia-inducible factor- 1 (HIF-1) complex is responsible for activating the 
transcription of genes in response to changes in tissue oxygenation
52
. HIF-1 is a 
heterodimer consisting of a HIF-1  and HIF-  subunit (Figure 8). Although HIF-1  is 
synthesized in healthy cells under conditions of normal oxygen concentration, it is 
hydroxylated by prolyl hydroxylases resulting in its recognition by von Hippel-Lindau 
tumour suppressor (VHL) and subsequent degradation
2
.  Upon exposure to hypoxia, the 
HIF-1  and HIF-  subunits become rapidly stabilized
53
. Oncogenic mTOR activation or  
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Figure 8. HIF-1 in the Warburg Effect.  The overall effect of HIF-1 on metabolism is 
consistent with the Warburg phenotype in that it promotes glycolysis while preventing 
oxidative phosphorylation. Activation of HIF-1 has been shown to promote the 
transcription of glucose transporters
54
 and glycolytic genes
55,56
. Additionally, it increases 
expression of PDK1 thereby inhibiting the flow of products into the citric acid cycle
57
.  
 
mutations in the tumour suppressor VHL can lead to HIF1 stabilization under normoxic 
conditions
53
. This occurs through increased translation of the hypoxia-inducible factor- 1 
(HIF-1)  subunit of the HIF complex due to enhanced mTOR activity
52
. 
     Evidence indicates that HIF-1 contributes to the Warburg effect by stimulating a 
number of genes that mediate glycolysis (Figure 8). In embryonic stem cells, lack of the 
HIF-1  subunit resulted in reduced GLUT1 and GLUT3 mRNA levels
54
. Although the 
GLUT1 and GLUT3 protein levels were not measured in this study, these findings 
Investigation of the Expression of Glucose Transporter Proteins in Human Cancer Cells 22 
suggest increased GLUT expression by HIF-1. HIF-1 has been shown to stimulate the 
transcription of a number of glycolytic genes that possess hypoxia-response elements in 
their promoters, these include aldolase, enolase or lactate dehydrogenase, and the enzyme 
6-phospho-2-kinase/fructose2, 6-biphosphatase
55,56
. In addition, HIF-1 stimulates mRNA 
and protein expression of pyruvate dehydrogenase kinase 1 (PDK1) which is responsible 
for phosphorylating and inhibiting the mitochondrial pyruvate dehydrogenase complex
57
. 
This prevents conversion of pyruvate into acetyl-CoA, leading to inhibition of the 
tricarboxylic acid cycle and enhancing production of lactate. 
 
1.4.3 Ras   
     Ras GTPases function as molecular switches in processes governing cell proliferation, 
survival, and differentiation
58
. The three mammalian ras genes encode the four classical 
Ras proteins of 21 kDa: H-Ras, K-Ras4A, K-Ras4B, and N-Ras. These proteins show 
remarkable similarity, they are identical over the 85 N-terminal residues, and their 
identity within the following 80 residues is up to 90%
58
. 
     A key function of Ras protein is to regulate the PI3K and the Mitogen Activated 
Protein Kinase (MAPK) signaling pathways. The Ras-MAPK signaling pathway can be 
seen in Figure 9. In the resting state, Ras binds to GDP. Ras proteins become active 
when bound to GTP, this occurs by tyrosine kinase receptor activation that inhibits 
GTPase activating proteins (GAPs) or activates guanine nucleotide exchange factors 
(GEFs)
58
. Most growth factors that signal through receptor tyrosine kinases (RTKs) or 
GPCRs activate Ras by recruiting the GEF Son of Sevenless (SOS) to the plasma  
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membrane
59
. SOS is found in a complex with the adaptor protein Growth Factor 
Receptor-Bound Protein-2 (GRB2). Similar to PI3K, the GRB2/SOS complex is 
translocated to the membrane by binding of GRB2 to phosphorylated tyrosine residues 
on RTKs or adaptor proteins
58
. GTP-bound Ras recruits and activates the serine/threonine 
kinase Raf. Activated Raf binds to and phosphorylates
 
the dual-specificity mitogen 
activated kinases (MEK1/2), which in turn, activate the extracellular regulated kinases 
 
 
Figure 9. The Ras-MAPK signaling pathway. Activation of the Ras-MAPK pathway by 
growth factors and mitogen leads to growth and differentiation
58
. While this pathway is 
essential to healthy cells, oncogenic mutations of Ras can result in uncontrolled 
growth
58,60
.  
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1/2 (ERK1/2) by phosphorylation within a conserved Thr-Glu-Tyr motif. Upon 
activation, ERK1/2 translocates into the nucleus where it phosphorylates substrates 
including the transcription factors c-jun, c-fos and c-myc
58
. Alternatively, activated Ras 
may activate the p110 catalytic subunit of PI3K, independently of p85, and lead to the 
subsequent activation of Akt as earlier described
59
. 
      In healthy cells Ras function is essential, however oncogenic mutations of Ras can 
lead to uncontrolled proliferation. Ras is found to be mutated in approximately 25% of 
human tumours
60
. Amino acid replacements at residue 12, and less commonly at residues 
13 and 61, lock Ras proteins in a GTP-bound state in which they signal to downstream 
effectors even in the absence of extracellular stimuli
58
.  
     In a study of NIH3T3 mouse fibroblasts transformed by an activated form of the K-ras 
oncogene, expression of lactate dehydrogenase and a number of glycolytic enzymes were 
found to be increased
60
. These cells consumed more glucose and produced more lactate 
than normal or reverted cells, providing evidence that Ras may play a role in the Warburg 
phenotype
60
.  
 
1.4.4 c-Myc 
     The MYC family of cellular oncogenes includes c-Myc, a transcription factor 
involved in the control of cell proliferation and death
61
. Myc also regulates genes 
involved in glucose metabolism. The targets of c-Myc are similar to HIF-1, in Rat-1 
fibroblasts, c-Myc has been shown to directly transactivate genes encoding GLUT1, 
phosphofructokinase, and enolase
62
. Furthermore, lactate dehydrogenase-A has been  
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identified as a c-Myc-responsive gene
63
. This suggests c-Myc and HIF-1 may cooperate 
together to enhance aerobic glycolysis and contribute to the Warburg effect (Figure 10).  
 
1.4.5 The tumour suppressor protein p53  
          Active p53 protein is composed of a tetramer made of four identical subunits, each 
consisting of an N-terminal transactivation domain, a proline-rich region, a DNA-binding 
core domain and, within the C-terminal regulatory domain, a tetramerization domain and 
an unstructured basic domain
64
. Wild type p53 is a sequence-specific DNA binding 
protein and transcription factor responsible for negatively regulating cell growth and 
division
65
. The p53 protein is activated by a variety of stress signals (Figure 11),  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. c-Myc in the Warburg Effect. The transcription factor c-Myc is suggested to 
contribute to the Warburg Effect by increasing the expression of genes that promote 
glycolysis
62
 and lactate production
63
 thereby enhancing aerobic glycolysis.  
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including DNA damage, and responds to the specific signal by initiation of cell cycle 
arrest, senescence or apoptosis among other outcomes
64
. The most common mutations of 
p53 are missense mutations that occur in the conserved DNA-binding domain in the 
central portion of the protein
64
. Most cancer-related mutations of p53 are clustered in the 
four 'hot spots' at codons 175, 248, 273 and 281/282
66
. In mutant p53 AS-30D hepatoma 
cells, overexpression of mutated p53 was found to significantly activate the promoter of 
hexokinase 2, the enzyme catalyzing the first step of glycolysis in which glucose is 
converted to glucose-6-phosphate
65
. In healthy cells, p53 blocks the glycolytic pathway 
by lowering levels of the glycolytic activator fructose-2,6-bisphosphate in cells through a 
gene identified as TP53-induced glycolysis and apoptosis regulator (TIGAR)
67
  (Figure 
12). This is also accomplished through inducing the expression of phosphatase and tensin 
homolog (PTEN), a tumour suppressor that inhibits activity of the PI3K pathway by  
 
 
 
 
 
 
 
 
 
Figure 11. The tumour suppressor protein p53. In healthy cells, the p53 protein is activated 
by stress signals and initiates responses to prevent the formation of tumours such as DNA 
repair, cell cycle arrest and apoptosis
64
.  Mutations in p53 are found in most cancers
64,66
.  
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removing a phosphate group from PIP3
68
. In mice with a homozygous (-/-) disruption of 
the TP53 gene, a significant decrease in oxygen consumption and mitochondrial 
respiration was observed
69
. These effects were found to be mediated by p53-induced 
transcription of synthesis of cytochrome c oxidase 2 (SCO2), which forms the 
cytochrome c oxidase complex of the electron transport chain
69
. Therefore, in addition to 
blocking glycolysis, p53 promotes oxidative phosphorylation. Loss of this gene may play 
an important role in contributing to the aerobic glycolysis observed in cancer cells.  
 
1.4.6 
18
Fluoro-deoxy-glucose positron emission tomography (FDG-PET) 
     Malignant cells show increased glucose uptake both in vitro and in vivo
70
. In order to 
achieve a glycolytic rate that is approximately 30 fold higher than normal, tumours must 
 
 
 
 
 
 
 
 
 
 
Figure 12. p53 in the Warburg Effect. In healthy cells, functional p53 induces the transcription of 
genes that promote oxidative phosphorylation and block glycolysis
64
. Cell with mutated or absent 
p53 lose these regulatory effects on metabolism
65,67-69
.   
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bring glucose into the cell at an elevated rate
70
. It is this characteristic that led to the 
development of a technique known as FDG-PET for tumour detection and monitoring
71
. 
18
Fluoro-deoxy-glucose is a positron emitter that can be detected by PET scanners. 
18
Fluoro-radiolabelled 2-deoxy-glucose analog is recognized as a substrate by glucose 
transporters. Tumour cells, with an increased rate of glycolysis, will have an increased 
uptake of FDG which serves as a substrate for hexokinase and is converted into its 6-
phospho derivative. The resulting compound is stable and will not be metabolized further, 
allowing its accumulation to be visualized. Since tumours have an increased rate of 
glucose uptake compared to normal cells, FDG-PET is able to detect tumours and 
differentiate them from healthy tissue. In this fashion, glucose uptake serves as a 
functional biomarker in cancer that allows physicians to determine the extent of the 
disease and to guide treatment.  
 
1.5 Regulation of Glucose Transporters  
1.5.1 Regulation of GLUT1 
     The serine/threonine kinase Akt has been shown to induce GLUT1 gene transcription. 
This was demonstrated in mouse hepatoma cells where a hydroxytamoxifen-regulatable 
form of Akt responded to stimulation by hydroxytamoxifen by increasing GLUT1 
transcription and protein accumulation
47
. Akt has also been implicated in the plasma 
membrane trafficking of GLUT1 in response to NF-κB transcription factors and cytokine 
stimulation
72-74
. 
     Furthermore, expression of a kinase inactive Akt1 inhibited the ability of insulin to 
induce GLUT1 mRNA expression in the study by Barthel et al. (1999), suggesting that 
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Akt is an important mediator through which insulin regulates GLUT1 gene expression
47
. 
Chronic insulin stimulation has been shown to increase GLUT1 protein levels
75,76
; 
inhibition of the p70 S6 kinase with rapamycin almost completely abolished the increase 
in GLUT1 protein in response to insulin indicating activation of this downstream kinase 
from Akt is required in the process
75
.  
     There is evidence that the ovarian hormone estrogen is capable of inducing GLUT1 
expression. In MCF-7 breast cancer cells, treatment with estrogen was found to increase 
glycolysis via upregulation of GLUT1 protein
77
. A decreased rate of glycolysis and 
GLUT1 expression was observed due to the antiestrogenic effects of tamoxifen treatment.  
     Certain stressors have been shown to increase expression of GLUT1. Long-term 
treatment with hyperosmolarity (300 mM mannitol) was found to increase GLUT1 
protein expression by 70%, and similar to insulin, this was mediated by the p70 S6 
kinase
76
. Supporting the notion that GLUT1 is a stress inducible protein, exposure of L6 
myotubes to prolonged low grade oxidative stress induced by glucose or xanthine oxidase 
was also shown to increase GLUT1 mRNA and protein levels
78
. Treatment with 2,4-
dinitrophenol (DNP), an uncoupler of oxidative phosphorylation that depletes ATP 
production, was shown to induce a 150% increase in GLUT1 protein expression
76
. This 
evidence suggests GLUT1 may be an important transporter for uptaking glucose to 
provide energy in low oxygen conditions.  
     Indeed, GLUT1 expression has been shown to be regulated by hypoxia through HIF-
1
54
. Hypoxia response elements (HRE) located on the GLUT1 gene contain HIF-1 
binding sites with the consensus sequence 5-RCGTG-3
79
. This was demonstrated using 
placental cell lines in which deletion of an 184bp hypoxia-HR of the rat GLUT1 
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promoter was found to reduce GLUT1 expression, indicating an important role of HIF-1 
in modulating GLUT1 gene expression in response to low-oxygen conditions
79
.  
     GLUT1 expression is up regulated by a number of oncogenes. c-Myc was found to 
induce GLUT1 gene expression in rat fibroblasts and livers
62
. A Rat1 fibroblast line 
expressing a protein that fuses Myc to the estrogen receptor ligand binding domain 
(MycER) was used to demonstrate GLUT1 behaves as a direct target gene of c-myc. This 
system uses exposure of the MycER protein to estrogenic compounds, such as 4-
hydroxytamoxifen (4-HOTM), to translocate the ligand-bound MycER protein to the 
nucleus where it can activate target genes without new protein synthesis. After activation 
of MycER by 4-HOTM, expression of GLUT1 was found to be increased.  
     Colorectal cells with mutations in K-Ras or v-raf murine sarcoma viral oncogene 
homolog B1 (BRAF) were shown to upregulate the GLUT1 gene and display enhanced 
glucose uptake, glycolysis, and survival in low-glucose conditions
80
. Very few cells 
survived when wild-type KRAS alleles were subjected to a low-glucose environment. 
However, 4% of survivors acquired KRAS mutations that were not present in their 
parents. This finding suggests that glucose deprivation may select for mutant cells with 
KRAS mutations which can be a growth advantage because of increased GLUT1 
expression.   
     Expression of the GLUT1 gene is down-regulated by the tumour suppressor gene 
p53
81
. Cotransfection of osteosarcoma-derived SaOS-2 cells, rhabdomyosarcoma-derived 
RD cells and C2C12 myotubes with GLUT1-P-Luc or GLUT4-P-Luc promoter-reporter 
constructs and wild-type p53 expression vectors was found to dose dependently decrease 
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GLUT1 and GLUT4 promoter activity. This highlights the link between GLUT1 
overexpression observed in various cancers and mutations in p53. 
     In addition to increasing the expression of this transporter, insulin has been shown to 
promote GLUT1 translocation to the plasma membrane
82
. Evidence indicates that insulin-
like growth factor I (IGF-I) is capable of regulating localization of GLUTs. In L6 
myotubes, acute stimulation with IGF-I did not increase expression of GLUT1 protein, 
however an increase in GLUT1 protein in the plasma membrane enriched fraction of cells 
was seen
83
. The translocation of GLUT1 by IGF-1 was found to be similar to that of 
insulin with respect to the increase in cell surface GLUT1 over basal levels
84
.  
 
1.5.2 Regulation of GLUT3 
     The serine/threonine kinase Akt has been implicated in the regulation of GLUT3 
expression. This was demonstrated in L6 skeletal muscle cells in which cells 
overexpressing wild-type Akt or a constitutively active membrane-targeted Akt displayed 
a significant increase in glucose uptake. The increased transport of glucose into the cell 
was found to be mediated by the cellular synthesis of GLUT3
46
.  
     Like GLUT1, long-term insulin stimulation has been shown to increase mRNA and 
protein expression of GLUT3
75,76
. In L6 myotubes, this was suggested to occur in a 
MEK/ERK dependent manner as inhibitors of both proteins resulted in a large reduction 
in the insulin-stimulated increase in GLUT3 protein
76
. There is also evidence suggesting 
GLUT3 to be a stress induced protein which may be regulated by similar pathways as 
GLUT1.  p70 S6 kinase has also been implicated in the increase in GLUT3 protein levels 
after long-term hyperosmolarity treatment
76
. Furthermore, like GLUT1, GLUT3 was  
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Table 2. Summary of known contributors/mediators of GLUT1 expression   
Contributor/mediator Tissue Effect on regulation Pathway Involved Reference 
Akt activation  Mouse hepatoma 
cells (Hepa1c1c7)  
FL5.12 
hematopoietic 
myeloid cells 
Increases transcription  mTOR/Raptor  47 
 
72-74 
Insulin Mouse hepatoma 
cells (Hepa1c1c7)  
L6 muscle cells 
Increases mRNA and 
protein expression 
Akt/mTOR/4E-BP1 47 
 
75,76,82 
Estrogen MCF-7 breast cancer 
cells 
 
Increases protein 
expression 
N/A 77 
Stress 
Hyperosmolarity 
(300 mM mannitol) 
 
2,4-dinitrophenol 
(0.5 mM) 
 
Oxidative stress 
( 50 milliunits/ml 
glucose oxidase,  20 
milliunits/ml xanthine 
oxidase) 
 
L6 muscle cell 
 
L6 muscle cell 
 
L6 muscle cell 
 
Increases protein 
expression 
 
 
Increases mRNA and 
protein expression  
 
Increases mRNA and 
protein expression 
 
p70 S6 kinase and p38 
MAPK dependent  
N/A 
 
 
Increases GLUT1 
transcription rate  
 
76 
 
76 
 
78 
Hypoxia/HIF-1 Trophoblast-derived 
human (BeWo) and 
rat (Rcho-1) cells  
Induces mRNA 
expression 
HIF-1 binding site on 
hypoxia response 
element 5-RCGTG-3 
79 
c-Myc  Rat1 fibroblasts Induces mRNA 
expression 
Directly transactivates 
SLC2A1 gene 
62 
K-ras Colorectal cancer 
cells 
Induces mRNA 
expression 
Directly transactivates 
SLC2A1 gene 
80 
B-raf Colorectal cancer 
cells 
Induces mRNA 
expression 
Directly transactivates 
SLC2A1 gene 
80 
p53  SaOS-2 cells,  
rhabdomyosarcoma-
derived RD cells, 
C2C12 myotubes 
Downregulates mRNA 
expression  
Represses promoter 
activity 
81 
IGF-I L6 muscle cells Regulates translocation 
to the plasma 
membrane 
N/A 83, 84 
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shown to possess an HRE and expression of this gene was induced by formation of the 
HIF-1α complex in response to hypoxia85. This has been demonstrated in a number of 
models including neurons and carcinomas
86-88
. 
     In murine brain and mouse neuroblastoma cells, it was confirmed that phosphorylated 
cyclic AMP-regulatory element-binding (pCREB)1 protein binds the GLUT3 promoter 
region and activates GLUT3 expression in neurons
89
. Cyclic-AMP (cAMP) signaling 
involves a conserved second messenger pathway which is regulated by heterotrimeric G 
proteins. These proteins transduce extracellular signals via G protein-coupled receptors 
and activate the enzyme adenylyl cyclase. This enzyme is responsible for the conversion 
of ATP to cAMP which then activates the cAMP-dependent protein kinase A. The 
transcription factor CREB is activated by protein kinase A by phosphorylation on Ser-
133. In the study by Rajakumar et al. (2004) GLUT3 gene expression was transactivated 
by Ser-133 phosphorylation of CREB that led to enhanced binding to the site of the 
transcription factor activator protein 1 (AP-1) on the GLUT3 gene
89
. The Sp family of 
transcription factors was also implicated in the regulation of GLUT3 expression. These 
proteins bind to genes with a DNA control sequence T GGGCGGAAT, otherwise known 
as a GC box, to regulate expression of multiple target genes. In the case of GLUT3, Sp3 
was found to activate gene expression by binding to a site in the 5’-flanking region of the 
gene, while Sp1 was found to functions as a repressor of GLUT3 expression when 
binding in this region.  
     In p53−/− mouse embryonic fibroblasts, the loss of p53 was found to activate the NF-
κB transcription factor and increase the rate of aerobic glycolysis and upregulate 
GLUT3
90
. This expression was reduced by knockdown of the kinases IKKα and IKKβ 
Investigation of the Expression of Glucose Transporter Proteins in Human Cancer Cells 34 
that allow for the activation of NF-κB, indicating that functional p53 may suppress the 
expression of GLUT3 by inhibiting this pathway. This is the first study demonstrating 
down-regulation of GLUT3 by the tumour suppressor GLUT3. Therefore, additional 
studies in other models are needed to clarify the regulation of this transporter by p53.  
     Acute insulin stimulation affects the localization of GLUT3 by inducing translocation 
to the plasma membrane
84
.  In comparison, IGF-I stimulation results in 67% greater cell 
surface levels of GLUT3 than insulin
84
. It is possible that IGF-I-mediated GLUT3 
translocation is responsible for the higher rate glucose uptake in the presence of IGF-I as 
compared to insulin. 
     The energy sensor AMP-activated protein kinase exists as a heterotrimer composed of 
a catalytic α subunit and regulatory β and γ subunits91. It is activated by metabolic 
stressors which deplete ATP and increase AMP levels, allowing AMP to bind to the γ 
subunit of AMPK. This induces a conformational change promoting phosphorylation on 
the AMPK α subunit by upstream kinases. Once activated, AMPK stimulates catabolic 
pathways while switching off anabolic pathways
91
. In neuronal cells, AMPK has been 
shown to facilitate the translocation of GLUT3 to the cell surface after excitation
92
. 
Indirect activation of AMPK by glutamate excitation resulting in an increased AMP:ATP 
ratio, or pharmacological activation of AMPK with  5-amino-1-β-D-ribofuranosyl-
imidazole-4-carboxamide (AICAR) resulted in increased GLUT3 surface expression. 
This was found to be prevented by inhibition of AMPK with compound C or knockdown 
with siRNA. However, in human embryonic kidney cells, AMPK was found to increase 
GLUT3-mediated glucose uptake in a manner that did not involve transporter 
translocation
93
. These findings suggest AMPK may have different regulatory effects on 
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GLUT3 depending on the cell type and stimulus. Further research to determine the 
mechanisms by which AMPK stimulates GLUT3-mediated glucose uptake is needed. 
Table 3. Summary of known contributors/mediators of GLUT3 expression   
Contributor/ 
mediator 
Tissue Effect on regulation Pathway Involved Reference 
Akt activation  L6 muscle cells Increases protein 
expression 
N/A 46 
Insulin  L6 muscle cells  Increases mRNA and 
protein expression  
MEK/ERK 
dependent  
 
75, 76  
Stress 
Hyperosmolarity 
(300 mM 
mannitol) 
 
 
L6 muscle cells 
 
Increases protein 
expression 
 
p70 S6 Kinase 
dependent  
 
76 
Hypoxia/HIF-1 Hep-G2 human 
hepatocellular carcinoma 
cells (ATCC HB 8095) 
L8 rat muscle cells, Hepa-
1c1c7 rat hepatoma cells, 
rat cerebrum and retina, 
BeWo choriocarcinoma 
cells 
Induces gene expression  HIF-1 binding site 
on hypoxia 
response element  
85-88 
cAMP-pCREB Mammalian neurons  Induces gene expression  Binding to 
transcription factor 
activator protein 1 
(AP-1) on the 
SLC2A3 gene 
89 
sp3 Mammalian neurons Induces gene expression  Binding to GC box 
on SLC2A3 gene 
89 
sp1 Mammalian neurons Represses gene 
expression  
Binding to GC box 
on SLC2A3 gene 
89 
p53 Mouse embryonic 
fibroblasts 
Downregulates mRNA 
expression 
Inhibition of NF-
κB pathway 
90 
IGF-I L6 muscle cells  Regulates translocation to 
the plasma membrane 
N/A 84 
AMPK 
activation 
Cerebellar granule 
neurons  
Human embryonic kidney 
cells (293T)  
Regulates translocation to 
the plasma membrane 
Increases activity of 
transporter  
N/A 92 
 
93 
Investigation of the Expression of Glucose Transporter Proteins in Human Cancer Cells 36 
1.5.3 Regulation of GLUT4 
     A 2.4 kb DNA segment at the 5′ region of the GLUT4 gene is responsible for tissue-
specific expression of GLUT4 in adipose tissue, skeletal muscle, and cardiac muscle
95
. 
The myocyte enhancer factor 2 (MEF2) proteins are a family of transcription factors that 
play a role in muscle differentiation and development
94
. A MEF2 binding site has been 
identified in the GLUT4 promoter that is necessary for expression in skeletal muscle
94
. A 
region −742 to −712 relative to the initiation site for transcription, termed Domain I, has 
also been has been implicated in tissue-specific expression of GLUT4
95
. A factor termed 
GEF appears to operate in this region in association with MEF2A
96
.  
     Downregulation of GLUT4 expression occurs in adipose tissue in obesity. This has 
been shown in obese and obese patients with type 2 diabetes in which adipocyte GLUT4 
protein and mRNA levels were significantly decreased compared to lean body mass 
controls
97
. This study is supported by Sinha et al. (1991) where decreased levels of the 
muscle/fat GLUT4 isoform were found in adipose tissue of patients with type 2 
diabetes
98
.  
     Upregulation of GLUT4 in skeletal muscle has been observed in response to exercise. 
This can be achieved by a single session of exercise, as seen in rats that experienced a 2-
fold increase in GLUT4 mRNA and a 50% increase in GLUT4 protein expression 16 
hours after a prolonged exercise session
99
. This has also been demonstrated in humans, 
exercise training was shown to increase GLUT-4 gene expression immediately after 
exercise and it remained elevated three hours after the end of exercise
100
. These effects 
have been suggested to occur through activation of the energy sensor AMP-activated 
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protein kinase (AMPK), as increasing AMPK activity with the AICAR was shown to lead 
to transcriptional activation of the GLUT4 promoter in rats
101
.  
     Like GLUT1 and GLUT3, expression of the GLUT4 gene may be down-regulated by 
the tumour suppressor gene p53
81
. The inhibitory effect of p53 on transcriptional activity 
of GLUT4 was found to be significantly greater than its effect on GLUT1. The reason for 
this difference is not understood but may reflects differences in the expression of the 
transporters since GLUT1 is ubiquitous and GLUT4 is tissue-specific.     
     In conditions of low plasma insulin, GLUT4 is stored in intracellular tubulo-vesicular 
compartments. Two motifs are responsible for the association of the protein with this 
compartment: a dileucine motif in the C-terminus and a FQQI motif in the N-terminus
30
. 
Upon insulin binding to its receptor, the PI3K and MAPK signaling cascades are 
activated, as previously described. In response to insulin, GLUT4 is rapidly translocated 
from endosomal compartments to the plasma membrane resulting in an increase in 
glucose uptake
29
. The precise pathways by which insulin signaling pathways control 
GLUT4 trafficking are still not fully understood. However, this is suggested to occur 
through Akt phosphorylation of the GTPase activating protein AS160. Knockdown of 
AS160 in adipocytes using short-hairpin RNA was found to increase basal GLUT4 levels 
on the adipocyte surface, suggesting that the role of this protein is to retain GLUT4 
intracellularly and this hold is relieved upon insulin stimulation
102
. Disruption in the 
regulation of GLUT4 translocation by insulin is one of the key defects in insulin 
resistance and type 2 diabetes mellitus
31
.  
     Acute IGF-I stimulation in L6 myotubes was found to induce GLUT4 translocation to 
the plasma membrane without affecting the total cellular content of this protein
83
. 
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Prolonged (8 hour) stimulation, however, was found to increase total GLUT4 protein 
levels and thus the level found in the cell surface. These findings suggest that similar to 
insulin, IGF-I has acute and chronic effects on glucose uptake that are mediated through 
glucose transporters.  
     In addition to increasing GLUT4 expression, AMPK has been implicated in GLUT4 
translocation that occurs after acute exercise. AICAR activation of AMPK is capable of 
increasing glucose uptake and GLUT4 translocation in skeletal muscle
103,104
. 
Table 4. Summary of known contributors/mediators of GLUT4 expression   
Contributor/
mediator 
Tissue Effect on regulation Pathway 
Involved 
Reference 
Obesity  Adipocytes Decreases mRNA and 
protein expression  
N/A 97, 98 
Exercise  Muscle Increases mRNA and 
protein expression  
N/A 99, 100 
 
AMPK 
activation 
Muscle Increases mRNA 
expression  
 
Regulates translocation to 
the plasma membrane 
Transcriptional 
activation of 
GLUT-4 promoter 
N/A 
101 
103, 104 
p53  SaOS-2 cells,  
rhabdomyosarcoma-
derived RD cells, 
C2C12 myotubes 
Downregulates mRNA 
expression  
Represses 
promoter activity 
81 
Insulin  Adiopocytes 
Muscle cells 
Regulates translocation to 
the plasma membrane  
Akt/AS 160 
dependent  
102, 48 
IGF-I 
(3-10 nM) 
L6 muscle cells Acute- Increases 
translocation to the plasma 
membrane 
Long-term- Increases 
protein expression   
N/A 83 
 
 
Investigation of the Expression of Glucose Transporter Proteins in Human Cancer Cells 39 
1.5.4 Regulation of GLUT12  
     There is limited evidence regarding the regulation of GLUT12. Given that other 
GLUTs have been shown to be regulated by estrogen, the effects of the hormones 17 -
estradiol and dihydrotestosterone on GLUT12 expression were examined in MCF-7 
cells
16
. Treatment with 17 -estradiol for up to 24 hours was found to have no effect on 
GLUT12 mRNA expression, however a significant increase in GLUT12 protein was seen 
was seen after treatment with 17 -estradiol or dihydrotestosterone for 24 hours. These 
findings suggest the GLUT12 mRNA translation rate or protein half-life may be 
increased by hormone treatment.  
     Additionally, this study looked at the effect of epidermal growth factor (EGF), a 
known activator of proliferation in breast cancer cells, on GLUT12 expression. While 
GLUT12 mRNA expression was found to significantly decrease after eight hours of 
treatment with 60 ng/ml EFG, an increase in GLUT12 protein was observed after two 
hours of treatment which began to decrease after 24 hours. Therefore, GLUT12 
expression appears to be regulated at the mRNA and protein level by EGF, the 
mechanism by which this is achieved and possible negative feedback loops after long-
term EGF treatment remain to be examined.  
     Similar to the previously mentioned GLUTs, there is evidence to suggest that 
repression of the SLC2A12 gene occurs by the tumour suppressor p53. Using a small 
compound that re-activates p53, termed reactivation of p53 and induction of tumour cell 
apoptosis (RITA), p53 was pharmacologically reconstituted in cancer cell lines and 
HCT116 and HCT116 TP53-/- xenografts grown in immunodeficient mice
105
. Upon p53 
reactivation, significant repression of the SLCA12 gene in HCT116 xenografts occurred. 
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Using chromatin immunoprecipitation (ChIP) sequencing it was shown that upon RITA 
treatment, p53 binds to a consensus site in the SLC2A12 gene. Taken together, these 
findings suggest that SLC2A12 is a direct target of p53 and the expression of GLUT12 
that occurs in cancer may be due to the mutation or loss of this tumour suppressor.  
     It has been shown in various cell lines that endogenous and overexpressed GLUT12 
localizes to intracellular compartments and the plasma membrane
42,106,107
. GLUT12 
contains dileucine motifs at the N-terminus and C-terminus similar to GLUT4
41
. There 
does not appear to be a continuous cycling mechanism for GLUT12, as plasma 
membrane associated GLUT12 is not endocytosed. In human skeletal muscle, insulin was 
shown to be capable of inducing translocation of GLUT12 to the plasma membrane
108
. 
This was confirmed in L6 myoblasts in which insulin stimulation caused a shift of 
GLUT12 from an intracellular location to the plasma membrane fraction. Inhibition of 
PI3K was found to block GLUT12 translocation in these cells, suggesting that activation 
of this pathway may be responsible for the translocation of this transporter in muscle.  
     In renal epithelial cells, it was demonstrated that treatment with high glucose (25 mM) 
and 10% serum causes translocation of endogenously expressed GLUT12 to the 
cytoplasm and plasma membrane
109
. GLUT12 was implicated in the increased glucose 
uptake observed after mitogen treatment and it was found that incubation with the mTOR 
inhibitor rapamycin decreased glucose uptake levels and restricted GLUT12 to a 
perinuclear location in these cells. The potential regulated trafficking of this transporter 
by mitogens and the mTOR pathway should be explored in additional tissues.          
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Table 5. Contributors/mediators of GLUT12 expression   
Contributor/mediator Tissue Effect on regulation Pathway Involved Reference 
Estrogen  MCF-7 
breast cancer 
cells  
Increases protein 
expression  
N/A 16 
 
Epidermal Growth 
Factor (EGF) 
(60 ng/ml) 
MCF-7 
breast cancer 
cells  
Transient increase in 
protein levels  
Long term decrease 
in mRNA and protein 
levels  
N/A 16 
 
p53 Various 
cancer cell 
lines  
Downregulates 
mRNA expression  
Binds to promoter 
of SCL2A12 gene  
105 
Insulin  Muscle Regulates 
translocation to the 
plasma membrane 
PI3K dependent  108 
mTOR activation Renal 
epithelial 
cells 
Regulates 
translocation to the 
plasma membrane 
N/A 109 
 
 
1.6 Cell Lines  
     Culture models are frequently used to investigate the physiology and biochemistry of 
cells. A primary culture can be established from a tissue that is fragmented, or dispersed 
by enzymatic or mechanical disruption. Once maintained in the appropriate growth 
medium, the first subculture will proliferate and these cells can be reseeded to give rise to 
a secondary culture, and so on.  Finite cell lines have no gross genetic changes and a 
diploid chromosomal number
110
. These cells show anchorage dependence and grow as a 
monolayer, ceasing growth once confluence has been reached
110
. Human cells grown in 
Investigation of the Expression of Glucose Transporter Proteins in Human Cancer Cells 42 
culture generally divide 50-100 times before entering into a senescent phase in which 
there is an observed decline in cell number
111
.  
     Unlike finite cell lines, continuous cell lines have the ability to proliferate for an 
unlimited number of cell generations. Highly aggressive cancers that have accumulated 
genetic changes necessary for unlimited growth may spontaneously become continuous 
cell lines when cultured in vitro
110
. In order to expand the lifespan of cells, treatment with 
viral genes or carcinogenic chemicals may be used to sequester proteins inhibiting cell 
division and cause acquisition of mutations making the cells immortal
110
. Continuous cell 
lines may be aneuploid and have altered growth characteristics including anchorage 
independence and a loss of contact inhibition and density limitation on growth
110
.  
     The amount of tissue available for a number of cancers is limited because acquiring 
tumour tissue is invasive, and in some cases not possible due to the location of the 
tumour. Furthermore, tumour tissue may contain varying amounts of non-malignant cells 
and supporting tissues. Immortalized cancer cell lines are frequently used as in vitro 
models in cancer research. There are a number of advantages to using a cell culture 
model to understand cancer biology. These cells resemble the primary tumour population 
but offer a homogenous population of cells with an unlimited replicative ability. 
Furthermore, cells that are cultured in vitro are grown in a controlled environment that is 
free from external factors that may affect the expression of certain proteins. The 
properties of the cell lines studied can be seen in Table 6.  
MRC-5 
The MRC-5 cell line was established in 1966 from the normal lung tissue of a 14-week 
old male fetus
112
. Previous research has indicated these cells are capable of 42 to 46 
Investigation of the Expression of Glucose Transporter Proteins in Human Cancer Cells 43 
population doublings before the onset of senescence
112
. A number of studies have used 
MRC-5 cells as an established model of non-cancerous human lung fibroblasts. 
SK-MES-1 
The SK-MES1 cell line was derived from the pleural effusion of a 65 year old Caucasian 
male with squamous cell carcinoma
113
.  
H460 
The H460 cell line was initiated in 1982 from the pleural fluid of a large cell lung cancer 
patient
114 
and is an established large cell lung cancer epithelial cell line.   
A549 
The A549 cell line was initiated in 1972 through in vitro cultivation of lung carcinoma 
tissue from a 58-year-old Caucasian male
115
. This is a human lung adenocarcinoma 
epithelial cell line.  
H1299 
The H1299 cell line was derived from the lymph node of a 43 year old Caucasian male 
with non-small cell lung cancer
116
.  
184B5 
The 184B5 cell line was established from normal mammary tissue from a 21 year old 
female obtained from a normal reduction mammoplasty
117
. This is a chemically 
transformed cell line that was established when cells from this tissue were exposed to 
benzo(a)pyrene, a carcinogenic polycyclic aromatic hydrocarbon. The 184B5 cell line 
appears to be immortal, but is not malignant. It is a human mammary epithelial cell line.  
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MDA-MB-231 
The MDA-MB-231 cell line was isolated from pleural effusions of a 51 year old female 
Caucasian with breast cancer
118
. This cell line does not express estrogen receptors and 
therefore has been widely used to examine non-hormone sensitive breast cancer.  
MCF-7 
The MCF-7 cell line was initiated from the pleural effusion in a 69 year old female 
Caucasian with breast adenocarcinoma
119
. This cell line possess cytoplasmic estrogen 
receptors that are able to process estradiol and these cells are capable of forming domes 
as seen in differentiated mammary epithelium. MCF-7 is an established and widely used 
a human breast adenocarcinoma epithelial cell model. 
PNT1A 
The PNT1A cell line was initiated from the prostate of a 35 year old male at post-
mortem
120
. This is a noncancerous prostate epithelium cell line that has been 
immortalized with the Simian vacuolating virus 40 (SV40).  
22Rv1 
The 22Rv1 cell line was derived from a serially propagated xenograft in mice after 
castration-induced regression and relapse of the parental CWR22 xenograft
121
. This cell 
line has been shown to express the androgen receptor. 22Rv1 is a human prostate 
adenocarcinoma epithelial cell line. 
LNCaP 
The LNCaP cell line was established in 1977 from a needle aspiration biopsy of the left 
supraclavicular lymph node of a 50 year old Caucasian male with metastatic prostate 
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carcinoma
122
. This cell line is both androgen receptor- and estrogen receptor-positive and 
has been used extensively as a model of hormone sensitive prostate cancer.  
PC-3 
The PC-3 cell line was derived from a 62 year old Caucasian male from the bone 
metastasis of a grade IV prostatic adenocarcinoma
123
. These cells do not express the 
androgen receptor and therefore are a widely used in vitro model of hormone insensitive 
prostate adenocarcinoma.   
 
Table 6. Cell line properties  
Cell Line Histology Mutation Status/ 
Hormone Responsiveness 
SK-MES-1 Lung squamous cell carcinoma  p53 null 
H460 Lung large cell carcinoma KRAS mutant 
LKB1 null 
PIK3CA mutation 
A549 Lung adenocarcinoma KRAS mutant 
LKB1 null 
H1299 Lung adenocarcinoma p53 null 
MRC-5 Lung fibroblast  No known mutations  
MDA-MB-231 Breast adenocarcinoma p53 null 
KRAS mutant 
Estrogen receptor negative 
MCF-7 Breast adenocarcinoma PIK3CA mutation 
Estrogen receptor positive  
184B5 Mammary epithelium No known mutations 
22Rv1 Prostate adenocarcinoma p53 null 
Androgen responsive 
LNCaP Prostate adenocarcinoma PTEN null 
Androgen responsive 
PC-3 Prostate adenocarcinoma  p53 null 
PTEN null 
PNT1A Prostate epithelium No known mutations  
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1.6.1 Glucose Transporter Expression in Tumours and Cancer Cell Lines 
     Previous studies have suggested that increased glucose uptake in malignant cells is 
associated with an increased expression of glucose transporter proteins. The expression of 
select members of the GLUT family has been studied in various cancers. The following 
will review findings of GLUT expression in lung, breast and prostate tumours and cancer 
cell lines.  
 
1.6.2 Glucose Transporter Expression in Lung Tumours and Cancer Cell Lines  
     Compared to healthy cells, tumour cells have been shown to increase the expression of 
GLUTs with a low Km for glucose in order to meet demands
42
. GLUT1 and GLUT3 have 
high affinities for glucose and have been detected in various histological types of lung 
cancer at both the mRNA and protein level
124
. Ogawa et al. found GLUT1 to be 
amplified more than GLUT3 in lung tumours, however both proteins were correlated 
with proliferating cell nuclear antigen (PCNA), a nuclear protein that increases when 
DNA is being synthesized, indicating that GLUT-mediated glucose uptake may aid in the 
proliferation of cancer cells
124
. 
     GLUT1 and GLUT3 have been detected by immunohistochemistry in poorly and 
undifferentiated non-small-cell lung cancer (NSCLC) tumours
71
. These findings are 
supported by a study by Kurata et al. in which expression of GLUT1 was found to be 
significantly higher in primary lung tumours than in normal lung tissue
125
. Analysis of 
autopsy samples from primary lung and liver tumours, normal tissues and metastatic liver 
tumours using reverse transcriptase PCR revealed no differences in GLUT1 expression 
between primary lung tumours and metastatic liver tumours. However, the expression of 
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GLUT3 and GLUT5 were found to be significantly higher in metastatic liver tumours, 
suggesting different GLUT expression patterns may exist between primary and metastatic 
tumours. Studies comparing other types of primary cancers and their metastatic tumours 
are needed.  
     Little data exists regarding the expression of GLUTs in lung cancer cell lines. In 
agreement with the findings from lung cancer tissue samples, A549 and H226 cells were 
found to have low basal expression of GLUT1
126
. In comparison, this study found that 
H1299 and H1650 cells expressed higher levels of GLUT1
126
. This study is supported by 
detection of GLUT1 in A549 cells by western blotting by Ito et al. (2002)
127
.  
     The expression of glucose transporters in the lung cancer cell line H460 was 
determined using oligonucleotide DNA microarray
128
. Compared to a control pool of 
RNA, levels of GLUT1 in H460 cells were found to be increased and GLUT3 expression 
was 1.5-1.7 fold higher than the control. Further in vitro studies are required to establish 
the basal expression of GLUTs in lung cancer cell lines.  
 
1.6.3 Glucose Transporter Expression in Breast Tumours and Cancer Cell Lines   
     Mixed evidence exists in the literature in regards to GLUT1 expression and breast 
cancer. Younes et al. found GLUT1 expression in only 42% of tumours and their findings 
are supported by subsequent studies in which GLUT1 was detected in only a portion of 
breast cancer tumours
129-131
. Contrary to these reports, Godoy et al. reported positive 
staining in 91% of the invasive ductal carcinomas analyzed with immunohistochemistry 
and high expression has been reported in other studies as well
132-134
. It is possible these 
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conflicting results are due to the method used to detect GLUT1 (immunohistochemistry 
vs. PCR) or differences in the histological types of breast cancer examined. 
     Expression of glucose transporter proteins that are not present in corresponding 
healthy cells has been documented in breast cancer
107
. This was observed in a study by 
Rogers et al. (2003) where GLUT12 expression at the mRNA and protein level was 
found in primary human breast cancers but not normal breast epithelium
42
. Furthermore, 
GLUT5 is highly expressed in human breast cancer but is absent in normal human breast 
tissue
135
. The presence of a high affinity fructose transporter (GLUT5) in neoplastic 
breast tissue indicates human breast cancer cells may have a specialized capacity to 
transport fructose. GLUT3 was detected at the mRNA and protein level in breast cancer 
tumours and found to be expressed at significantly higher levels in poorly differentiated 
tumours
136
, suggesting this transporter may a useful marker in breast cancer staging.  
     Breast cancer cell lines are the most extensively studied with respect to GLUT 
expression. Hexose uptake assays and immunoblotting experiments have revealed that 
the breast carcinoma cell lines MCF-7 and MDA-468 express the glucose transporters 
GLUT1, GLUT2 and GLUT5
135
. GLUT1 expression is found more consistently in breast 
cancer cell lines than in tumours. When the invasiveness of the human breast cancer lines 
MCF-7, MDA-MB-435 and MDA-MB-231 was measured using an in vitro assay and 
compared with GLUT expression, it was found that GLUT1 protein levels increased with 
invasive potential
137
. GLUT2 and GLUT5, on the other hand, were found to be inversely 
associated with invasiveness
126
. GLUT3 was also detected in all three cell lines but did 
correlate with invasiveness.  Therefore, data regarding expression of specific GLUTs in 
cancer cell lines may be indicative of prognosis in breast cancers.  
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      Estrogen-receptor positive MCF-7 cells and estrogen-receptor negative MDA-MB-
231 cells are used to represent models of early- and late-stage breast cancer, respectively. 
Since both cell lines display high rates of fructose transport and increased levels of 
GLUT5 mRNA and protein, Chan et al. performed GLUT5 knockdown by antisense 
oligonucleotide and found a decrease in cell proliferation
138
. This suggests gene 
silencing/down regulation of GLUT5 as an attractive therapy for breast cancer because it 
was effective in both an early and late stage model of breast cancer. 
     The GLUT12 protein has been demonstrated in the breast cancer cell lines MCF-7 and 
T-47D
16,41
 while no detection was observed in the MDA-MB-231 and MDA-MB-435 cell 
lines. Expression of this transporter in other breast cancer cell lines remains to be 
investigated.  
 
1.6.4 Glucose Transporter Expression in Prostate Tumours and Cancer Cell Lines 
     Limited and conflicting evidence exists regarding GLUT expression in prostate 
cancer. A study using immunohistochemistry found that while healthy prostate tissue 
expressed GLUT3 and GLUT5, prostate carcinoma did not
132
. In this study GLUT1 was 
detected in prostate carcinoma at lower expression levels than in the normal tissue
132
, 
however other studies have failed to detect any GLUT1 protein expression in prostate 
tumours
139-141
. The protein responsible for glucose transport in prostate cancer may be 
GLUT12 as it was detected both at the mRNA and protein level in hyperplastic tissue 
sections
107
. Additionally, GLUT11 mRNA has been found to be up-regulated in prostate 
cancer as compared to benign prostate tissue
141
.  
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     The evidence regarding GLUT expression in prostate cancer cell lines is also 
extremely limited. GLUT1 mRNA has been detected in the DU145, PC-3 and LNCaP 
prostate cancer cell lines
142
. Additionally, a study using LNCaP cells and its derivatives 
C4, C4-2 and C4-2B indicated the presence of GLUT1 and GLUT12 mRNA in all cell 
lines examined
107
. Western blot analysis and immunofluorescence revealed the presence 
of the GLUT1 and GLUT12 proteins in these cell lines as well. These results are in 
contrast to the expression pattern observed in malignant prostate tissue which was 
negative for the GLUT1 protein
107
. Thus there is a need to address the relationship 
between GLUT expression in cancer cell lines and human tissues of the same cancer 
type.  
 
1.7 Rationale 
     It is well established that tumour cells display an increased rate of glucose uptake and 
utilization compared to non-cancerous cells
4,143
. Therefore, it is important to understand 
the mechanisms by which these processes are achieved. Tumour cells may compensate 
by upregulating GLUT proteins. This hypothesis is supported by evidence that elevated 
expression of glucose transporters has been observed in most cancers
144
. Moreover, some 
cancers also show an abnormal tissue expression pattern compared to healthy 
tissues
42,132,135
. Deregulated expression of GLUTs, with different hexose affinities, may 
allow cancer cells to optimize their energy supply providing a fundamental advantage for 
growth.  
     Elevated uptake of glucose allows tumours to be visualized using FDG-PET, currently 
used for the diagnosis and staging of cancers. Higher glucose uptake on FDG-PET scans 
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is often correlated with more aggressive and advanced-staged tumours
145.
. A positive 
relationship between tumour retention of FDG and GLUT1 expression has been observed 
in a number of cancer types
146-151
 suggesting that GLUT1 may serve as a prognostic 
biomarker in tumours. However, some studies have failed to find an association between 
FDG uptake and GLUT1 expression
152,153
. This indicates that other GLUTs may be 
responsible for the increased glucose uptake in these tumours and warrants the 
investigation of the expression of multiple GLUTs in cancer. 
     Another protein potentially responsible for the high rates of glucose uptake observed 
in cancer cells is the high affinity transporter GLUT3. Previous studies have detected this 
protein in various tumours
71,132,154
, however its expression in cancer cell lines is less 
clear. Given the stimulatory effect of mitogens and growth factors on cancer cell growth, 
it is also important to understand cancer expression patterns of GLUTs that are regulated 
by these substances. These include GLUT4, normally restricted to insulin-sensitive 
tissues, and GLUT12 which has been described in breast and prostate tumours
42,107
. It is 
possible stimulation by mitogens and/or growth factors increase the expression of these 
GLUTs and GLUT4- and GLUT12-mediated glucose uptake by cancer cells. 
Furthermore, GLUT4 and GLUT12 have been suggested to be transcriptionally repressed 
by the tumor suppressor p53, indicating these proteins may facilitate tumor growth in 
cancers with mutated p53
81,105
.  
     Limited data exists regarding the expression of GLUT4 in cancer. Previous studies 
show it has been sporadically detected in lung cancer tissue
140,152
, however its expression 
has not been investigated in cancer cell lines. Although GLUT12 was originally 
identified in a breast cancer cell line, little work has been done subsequently to 
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characterize its expression in other cancer cells. Although there is some evidence to 
indicate that GLUTs 5, 8, 10 and 11 are expressed in cancer
140
, the focus of this study 
was restricted to GLUT1, GLUT3, GLUT4 and GLUT12 due to the limited amount of 
commercially available products detecting GLUTs. Examining expression of the selected 
transporters in cancer cell lines will provide insight regarding which transporters may be 
facilitating the high rates of glucose uptake in tumours.  
     Support for GLUT expression as a prognostic indicator comes from studies that have 
found the expression of GLUTs to be associated with poor survival. This has been best 
studied with regards to GLUT1 and GLUT3. High expression levels of GLUT1 has been 
shown to be an indicator of poor survival in lung
71
, pancreatic
155
, colorectal
156
, ovarian
157
, 
breast
158
, bladder
159
 esophageal
160
 and oral cancer
161
 . A high level of GLUT3 expression 
has been shown to be associated with poor survival in lung
71
, laryngeal
162
 and oral 
cancer
161
. Furthermore, GLUT1 is an established marker of hypoxia which is a poor 
prognostic factor due its involvement in tumour resistance to radiotherapy and 
chemotherapy
163
. With increased knowledge about GLUT expression in aggressive 
cancers, these proteins can be used to help evaluate anticancer therapies by serving as 
biomarkers of tumour response to treatments. Therefore, understanding GLUT expression 
in cancer will aid in both monitoring tumours and planning a course of therapy. 
     Given that glucose uptake across the plasma membrane is considered the rate-limiting 
step for glucose consumption in tumour cells, this represents an ideal point to target for 
cancer therapy. Recent studies have focused on inhibiting the glucose transporter GLUT1 
in order to prevent cancer cell growth. Incubation with an anti-GLUT1 antibody was 
shown to decrease cell proliferation and induce apoptosis in NSCLC and breast cancer 
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cell lines
164
. In addition, the anti-GLUT1 antibody was found to have a synergistic effect 
with the anti-cancer drugs cisplatin, paclitaxel and gefitinib in enhancing apoptosis. The 
glucose transporter inhibitor fasentin has been shown to increase apoptosis in prostate 
cancer and leukemia cells by sensitizing these cells to the death ligand FAS
165
. 
Furthermore, the flavonoid apigenin has been found to inhibit proliferation of prostate 
cancer cells by decreasing GLUT1 expression at both the mRNA and protein level
166
. 
Taken together, the results of these studies suggest that preventing glucose uptake by 
blocking glucose transporters is an attractive therapeutic strategy for the treatment of 
various cancers. Identification of novel inhibitors of glucose transport is important and 
the small-molecule compounds WZB27 and WZB115 have recently been shown to 
inhibit glucose transport in lung, breast, colon and cervical cancer cells more potently 
than fasentin or apigenin
167
. 
     The increased dependence of tumour cells on sugars and the glycolytic pathway to 
generate ATP, along with the potential use of GLUTs as biomarkers and targets for 
therapeutics, provide important reasons to study GLUT expression in cancers. Although 
studies have indicated that cancer cells have increased and deregulated expression of 
GLUTs, a comprehensive understanding of the basal levels of glucose transporter 
expression in cancer is lacking. Expression and localization of the GLUTs in cancer cell 
lines has been studied less extensively than in tumour models. It is important to study 
GLUT expression in cell culture models as a first step in understanding the mechanism of 
glucose uptake by cancer cells and the function of these proteins. By using cancer cell 
lines, a uniform population of cells is available that will provide information about 
baseline expression patterns of GLUTs, not affected by hypoxia or treatment a patient 
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may be receiving. Established cancer cell lines are readily attainable and can be easily 
manipulated in future studies determining the function and regulation of GLUT proteins 
in cancer. Therefore, there are many advantages to studying GLUT expression in cancer 
cell lines rather than tumours.  
     As certain mutations have been shown to affect glucose transporter expression and 
distribution (See Regulation of Glucose Transporters), it is important to include cancer 
cells with different mutation statuses in the analysis of GLUT expression in cancer. The 
investigation of glucose transporter expression in a number of cancer cell lines, with 
different mutations and histologies, is important to provide a clear understanding of the 
role of GLUT proteins in cancer cell metabolism. 
 
1.8 Hypotheses  
In the present study it is hypothesized that: 
1) Lung, breast and prostate cancer cells display an increased and abnormal pattern 
of GLUT expression compared to non-cancerous cells of the corresponding tissue 
type  
2) Mutation status of oncogenes and tumour suppressor genes mediates specific 
patterns of GLUT expression  
3) Epithelial tumour cells may express multiple GLUTs  
4) Expression patterns of GLUTs in human tumours will be similar to that detected 
in tissue culture models of cancer  
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1.9 Objectives  
The primary objectives of the study are to: 
1) Examine the expression of the glucose transporters GLUT1, GLUT3, GLUT4 and 
GLUT12 at the mRNA level in lung, breast and prostate cancer cell lines as well 
as the corresponding non-cancerous cell lines of that tissue  
2) Examine the expression of the glucose transporters GLUT1, GLUT3, GLUT4 and 
GLUT12 at the protein level in lung, breast and prostate cancer cell lines as well 
as the corresponding non-cancerous cell lines of that tissue 
3) Determine the expression of GLUT1 and GLUT3 in tumours from nude mice 
xenografted with cancer cell lines  
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CHAPTER 2: METHODOLOGY 
2.1 Materials 
All tissue culture materials including Dulbecco’s Modified Eagle Medium (D-MEM), 
Roswell Park Memorial Institute (RPMI)-1640 medium, fetal bovine serum (FBS), 
trypsin and antibiotic were purchased from GIBCO Life Technologies (Burlington, ON). 
Antibodies against GLUT3, GLUT4 and GLUT12 were purchased from Abcam 
(Cambridge, MA) and antibodies against GLUT1 and GLUT4 were purchased from 
Serotec (Toronto, ON). HRP-conjugated anti-rabbit secondary antibody and actin 
antibody were purchased from New England Biolabs (Mississauga, ON). Alexa Fluor 
568 antibody was obtained from Molecular Probes (Hamilton, ON). The ECL Western 
Blotting Analysis System and SYBR Premix Ex TAQ DNA were obtained through 
Thermo-Fischer (Ottawa, ON). Polyvinylidene difluoride (PVDF) membranes, molecular 
weight protein standards and electrophoresis reagents were purchased from BioRad 
(Mississauga, ON). The RNeasy Mini Kit was purchased from Qiagen (Mississauga, ON) 
and SuperScript III First-Strand Synthesis SuperMix from Invitrogen (Burlington, ON). 
DNA-free was obtained from Ambion (Austin, TX). Vector biotinylated secondary, ABC 
reagent and Novared were obtained from Vector Laboratories (Burlington, ON). All other 
chemicals, including NaOH, HCL, NaCl and albumin bovine serum (BSA) were 
purchased from Sigma (St. Louis, MO). The MRC-5, SK-MES, H460, A549, H1299, 
184B5, MDA-MB-231, MCF-7, PNT1A, 22Rv1, LNCaP and PC-3 cells were purchased 
from American Type Culture Collection (ATCC). The L6 cells were a kind gift of Dr. A. 
Klip (Hospital for Sick Children, Toronto, ON). The C2C12 cell lysate was a kind gift 
from Dr. Jeff Stuart (Brock University, St. Catharines, ON).  The anti-GLUT1, -GLUT3 
Investigation of the Expression of Glucose Transporter Proteins in Human Cancer Cells 57 
and -GLUT4 small interfering RNA (siRNA) transfection kit was obtained from Qiagen 
(Mississauga, Ontario, Canada). 
 
2.2 Buffers and Solutions  
The composition of each buffer and solution that will be used to perform the experiments 
is presented below: 
Cell Lysis: 
PBS Washing Buffer: 137mM NaCl, 2.7mM KCl, 1.5mM KH2PO4, 8.1mM NA2HPO4, 
0.68mM CaCl2, 0.49mM MgCl2, add water to 1L and adjust pH to 7.4.  
SDS Sample Buffer: 62.5mM Tris-HCl (pH 6.8), 10% glycerol 2% w/v SDS,  
0.01% bromophenol blue, add 0.05% β-mercaptoethanol before use. 
 
Cell Lysis Buffer: 20mM Tris (pH 7.5), 150mM NaCl, 1mM EDTA, 1mM EGTA, 1% 
Triton X-100, 2.5mM sodium pyrophosphate, 1mM β-glycerolphosphate, 1mM Na3VO4, 
1µg/ml leupeptin, and add 1mM PMSF before use and chill on ice.  
 
Western Blotting: 
1.5M Tris-HCl Buffer (pH 8.8): 27.23g Tris base (18.15g/100ml), 80ml deionized water, 
adjust to pH 8.8 with 6N HCl. Bring to total volume 150ml with deionized water. 
0.5M Tris-HCl Buffer (pH 6.8): 6g Tris base, 60ml deionized water, adjust to pH 6.8 with 
6N HCl and bring total volume to 100ml with deionized water. 
Resolving Gel Buffer: 33% v/v of 30% Acrylamide/ Bis Solution, .38M Tris-HCl, pH 
8.8, .l% w/v SDS, bring to total volume 30ml with deionized water. Right before pouring 
the gel, add 150µl 10% APS made fresh daily and 15µl TEMED and swirl.  
Stacking Gel Buffer: 13.3% v/v of 30% Acrylamide/ Bis Solution, .13M Tris-HCl, pH 
6.8, .1% w/v SDS, bring to total volume 30ml with deionized water. Right before pouring 
the gel, add 150µl 10% APS made fresh daily and 30µl TEMED and swirl. 
10x TBS (Tris-buffered saline): .20M Tris base, 1.65M NaCl, adjust pH to 7.6 with HCl. 
Use at 1x TBS. Dissolve in 1L of water.  
Blocking Buffer:1x TBS, 0.1% Tween- 20 (100%), 5% w/v nonfat dry milk. Dissolved in 
water.  
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Wash Buffer TBS/T: 1x TBS and 0.1% Tween- 20 
Primary Antibody Dilution Buffer: 5% w/v nonfat dry milk in TBS/T 
10x Electrode Running Buffer: .13M Tris base, .96M Glycine, .017M SDS. Dissolve and 
bring volume to 500ml with DD water. Do not adjust pH with acid or base. Dilute 50ml 
of 10x stock with 450ml water before use. 
Transfer Buffer: 25mM Tris base, 0.2M glycine, 20% methanol, dissolved in 800ml of 
water.  
Polymerase Chain Reaction (PCR): 
cDNA Synthesis Mix: 2 l 10X Reverse Transcriptase (RT) Buffer, 4 l 25mM MgCl2, 2 
l 0.1 M Dithiothreitol (DTT), 1 l RNaseOUT (40 U/ l) and 1 l Superscript III RT 
(200 U/ l) per reaction.   
Primer Pair Master Mix: 0.5 l of 10 pmol/ l primer FORWARD, 0.5 l of 10 pmol/ l 
primer REVERSE, 2.75 l H20 and 6.25 l SYBR Green Premix per reaction.  
 
2.4 Cell Culture Techniques 
A549, H1299, H460, PC-3, PNT1A and 22Rv1 cell lines were grown in RPMI media 
supplemented with 10% (v/v) FBS and 1% (v/v) antibiotic-antimycotic solution (100 
U/ml penicillin, 100 g/ml streptomycin and 250 ng/ml amphotericin B). LNCaP cells 
were grown in RPMI media supplemented with 10% (v/v) FBS 1% (v/v) antibiotic-
antimycotic solution, 10 mM HEPES buffer and 1 mM sodium pyruvate. SK-MES, 
MRC-5, MCF-7 and MDA-MB-231 cell lines were grown in D-MEM media 
supplemented with 10% (v/v) FBS, and 1% (v/v) antibiotic-antimycotic solution. The 
cells were maintained until they reached 80-90% confluency with the media replaced 
every 2-3 days.  
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2.5 Cell Pellet Preparation  
All cell lines were grown in 75cm
2
 flasks and two flasks per passage per cell line were 
collected as cell pellets. Once 80-90% cell confluency was reached, cells were washed 
twice with PBS. Two milliliters of trypsin was added to each flask to detach cells which 
were collected in PBS and centrifuged at 10,000 rpm for 5 minutes. The PBS was 
aspirated from each tube and the cell pellet was washed by adding 1 mL of PBS to each 
tube and breaking the pellet. The cells in PBS were centrifuged again at 4,000 rpm for 5 
minutes. The PBS was aspirated from the tube and the samples were stored immediately 
at -80°C for further use in Real-Time PCR.  
 
2.6 Real-Time PCR 
Total RNA was purified from cell pellets using the Qiagen RNeasy Mini Kit following 
the manufacturer’s protocol. After RNA was eluted it was treated with the DNA-free kit 
by Ambion to eliminate any DNA contamination within the RNA samples. Next, a 
spectrometer was used to determine the concentration of the RNA samples. Equal 
amounts of RNA (up to 5 g) were used to synthesize cDNA using the SuperScript III 
First-Strand Synthesis Supermix protocol by Invitrogen. Previously designed forward 
(FOR) and reverse (REV) primers were used to amplify human GLUT3, GLUT4, 
GLUT12, RPII-1 and RPII-2. These primers were designed based on modifications to 
existing PCR primer pairs for gene expression detection and quantification listed in 
PrimerBank, with annealing temperatures of 60°C (http://pga.mgh.harvard.edu/primer- 
bank/index.html). The GLUT 1 FOR and REV primers were designed with assistance 
from a post-doctorate fellow using Primer Bank. These primers have been efficiency 
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tested and the integrity of the product has been verified by gel electrophoresis (Figure 
s.1). 
The sequence of the primers used are as follows:  
GLUT1: FOR 5’-CCTGCAGGAGATGAAGGAAG-3’  
REV 5’-TCGAAGATGCTCGTGGAGTA-3’ 
GLUT3: FOR 5’-GCTGGGCATCGTTGTTGGA -3’  
REV 5’-GCACTTTGTAGGATAGCAGGAAG -3’ 
GLUT4: FOR 5’-TCG GGC TTC CAA CAG ATA GG -3’  
REV 5’-AGC CAC GTC TCA TTG TAG CTC -3’ 
GLUT12: FOR 5’-CGG TTT CTG GTG ATG AAA GG -3’  
REV 5’-TCC GCA TGT TGT CTT TTG AA -3’ 
RPII-1: FOR 5’-GGGTG CTGAGTGAGAAGGAC-3’  
REV 5’-AGCCAT CAAAGGAGATGACG-3’  
RPII-2: FOR 5’- GAAACGGTGGACGTGCTTAT-3’  
 REV 5’-TCTC CATGCCATACTTGCAC-3’  
     The cycling conditions used are as follows: 95°C for 1 min, 40 total cycles of 95°C for 
10 sec, 60°C for 25 sec, and melt peak determination (95°C for 15 sec, increasing from 
65°C to 95°C with 0.5°C increments for 5 sec each). Parallel reactions were carried out 
for the RPII housekeeping gene to calculate relative mRNA levels by real time PCR 
using the 2
-[Δ][Δ]Ct
 method. RPII-1 was used for GLUT3, GLUT4 and GLUT12, and RPII-
2 was used for GLUT1.  
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2.7 Cell Lysis  
All cell lines were grown in 75cm
2
 flasks and two flasks per passage per cell line were 
collected for cell lysates. Once 80-90% cell confluency was reached, cells were washed 
twice with PBS and placed on ice. PBS was removed and 1.5 mL of lysis buffer was 
added to each flask. Cells were lysed and collected into 1.5 mL eppendorf tubes and 
stored at -20°C. 
 
2.8 Protein Assay 
Protein assay dye (BioRad) was prepared and filtered for protein concentration 
determination. A standard protein curve was created using BSA protein standards at 0, 
0.1, 0.2, 0.4, 0.6, 0.8, 0.9 and 1.0mg/ml. 10 l of each protein standard and the same of 
each of cell lysate was transferred in triplicate into separate wells of a 96-well plate. 
200 l of protein assay dye was then added to each well. A microplate was used to 
measure absorbance at 595nm and the final concentration of the protein samples was 
determined.  
 
2.9 Western Blotting  
An equal amount of SDS sample buffer was added to each cell lysate and the samples 
were then boiled for 5 minutes followed by centrifugation for 5 minutes. A total of 30-50 
μg of each protein was subjected to SDS-PAGE electrophoresis on 10% polyacrylamide 
gels. Samples were then transferred from the gel to a PVDF membrane and incubated in 
blocking buffer for 1 h at room temperature. The membrane was then incubated in 
primary antibody solution overnight at 4°C. After washing in TBS/T, the membrane was 
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incubated with the appropriate HRP-conjugated secondary antibody for 1h at room 
temperature. Signals were detected using the ECL Plus Western Blotting Detection 
System and exposure to film. Densitometric analysis was performed using ImageJ 
software. 
 
2.10 Immunohistochemistry 
Tumour tissues fixed in formalin from Balb/c nude mice xenografted with A549, H1299 
and PC-3 cells were obtained from the Translational Biology lab at the Juravinski Cancer 
Centre, Hamilton, ON. Four µm thick tumour sections were mounted onto slides and then 
deparaffinized by washes in xylene, ethanol and distilled water, respectively. Antigen 
unmasking was performed by boiling slides in 10 mM sodium citrate buffer for 30 
minutes. Slides were then blocked with 5% normal goat serum in TBS/T at room 
temperature for one hour followed by incubation with primary antibody against GLUT-1 
(1:250 dilution) or GLUT-3 (1:100 dilution) overnight at 4°C. Slides were incubated in 
Vector biotinylated secondary for 30 minutes, washed in TBS/T and then incubated in 
Vector ABC reagent for an additional 30 minutes. Vector Novared was used to stain 
slides that were then washed in distilled water and counterstained with hematoxylin. 
Slides were dehydrated with washes in ethanol followed by xylene and then mounted. 
Signals of antibody localization in the plasma membrane and cytoplasm were evaluated 
by a trained pathologist.  
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2.11 Immunofluorescence Microscopy  
Cells were grown on coverslips in 6-well dishes then washed with cold PBS and fixed 
with 4% formaldehyde in PBS for 20 minutes at room temperature. Cells were washed 
with PBS then permeabilized and blocked with 0.5% triton-X and 5% FBS in PBS for 
one hour at room temperature. The cells were then incubated with primary antibody 
against GLUT-4 (1:100 dilution) overnight at 4°C. The slides were washed with PBS and 
incubated with anti-rabbit secondary antibody conjugated to Alexa Fluor 568 for one 
hour in the dark. After staining with DAPI for 5 minutes, the slides were mounted and 
examined immediately using appropriate excitation wavelength.  
 
2.12 Small Interfering RNA (siRNA) 
Cells were incubated with Hyperfect transfection reagent without or with siRNA against 
GLUTs for 24 hours. The transfection reagent was removed and cells were incubated for 
an additional 72 hours before collection or fixation.  
 
2.13 Statistical Analysis  
Real time PCR Ct values were normalized first to the housekeeping gene RPII-1 
(GLUT3, GLUT4, GLUT12) or RPII-II (GLUT1). Values were then normalized to the 
appropriate noncancerous cell line (Figures 13-21) or to MRC-5 (Figures s.4-7) or the 
lowest GLUT expressed within that cell line (Figures s.8-10). Arbitrary densitometric 
values obtained from western blots were normalized first to the corresponding actin 
bands, then normalized to the appropriate noncancerous cell line. Statistical analysis was 
performed using SPSS v19.0 software. The results are presented as a mean +/- SEM of at 
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least three separate experiments. The assumptions of analysis of variance (ANOVA) were 
checked and data was analyzed by one-way ANOVA followed by a Tukey post-test to 
determine statistical differences between mean expression in cancer cells and the 
respective control cell line. Statistical significance was assumed at P<0.05.  
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CHAPTER 3: RESULTS 
3.1 GLUT1 Expression in Cancer Cells  
3.1.1 Lung Cancer Cells 
     The expression of GLUT1 was evaluated at the basal mRNA level through 
quantitative Real-Time PCR in SK-MES-1, H460, A549 and H1299 epithelial lung 
cancer cell lines and the noncancerous lung fibroblast line MRC-5 (Figure 13 A). 
Relative quantification revealed that GLUT1 mRNA levels were elevated in SK-MES-1 
cells compared to MRC-5 cells (4.30  0.61, p<0.01). GLUT1 mRNA levels were also 
higher in H460 cells (1.93  0.63, NS), while A549 (0.7  0.059, NS) and H1299 (.12  
0.004, NS) cells showed lower levels of GLUT1 mRNA in comparison to the MRC-5 cell 
line.  
     GLUT1 protein expression has been documented in a number of cancers
16, 29, 132
. 
Western blotting was performed to examine whether the observed mRNA expression of 
GLUT1 in the lung cancer cell lines corresponded with expression of the GLUT1 protein  
(Figure 13 B). Similar to the mRNA data, SK-MES-1 cells had higher levels of GLUT1 
protein compared to the MRC-5 cell line (193.75%  9.87%, p<0.01). Similar patterns 
were observed between the mRNA and protein expression of GLUT1 in the H460 
(138.84  27.53%, NS) and A549 (55.17  13.78%, NS) cell lines. In contrast to the low 
mRNA expression of GLUT1 in the H1299 cell line, expression of GLUT1 protein was 
88% higher compared to MRC-5 cells (188.67  6.79%, p<0.05).    
3.1.2 Breast Cancer Cells 
     GLUT1 mRNA expression in the breast cancer cell lines MDA-MB-231 and MCF-7 
was normalized to the mammary epithelial cell line 184B5 (Figure 14 A). The estrogen- 
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independent cell line MDA-MB-231 showed 1.57 fold higher GLUT1 mRNA expression 
compared to 184B5 cells (1.57  0.32, NS), while estrogen-responsive MCF-7 cells had 
lower expression than the noncancerous mammary cell line (0.33  0.037, NS).  
 
 
 
Figure 13. GLUT1 expression in lung cancer cells. A) Basal GLUT1 mRNA levels were 
determined by Real Time PCR and are expressed as a fold change of the lung fibroblast 
cell line MRC-5. B) Whole cell lysates were used in immunoblotting with a specific 
antibody that recognizes GLUT1. A representative immunoblot is shown. The 
densitometry of the bands expressed in arbitrary units was calculated using Image J 
software. Protein levels are expressed as a percentage of the MRC-5 cell line. Results 
represent the mean ± SEM of three to four independent experiments. (*p<0.05, 
**p<0.01).  
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     GLUT1 protein expression in the breast cancer cell lines was analyzed as arbitrary 
values (Figure 14 C) and normalized to the noncancerous cell line MRC-5 (Figure 14 D)    
 as it was not possible to obtain 184B5 cells for cell lysate preparation during the course 
of the study. Densitometric analysis of western blotting revealed that like the mRNA 
data, the MDA-MB-231 cell line showed a stronger expression of the GLUT1 protein 
than MCF-7 cells . When compared to the MRC-5 cell line, the MDA-MB-231 (232.9  
 
Figure 14. GLUT1 expression in breast cancer cells. A) Basal GLUT1 mRNA levels were 
determined by Real Time PCR and are expressed as a fold change of the mammary epithelial 
cell line 184B5. B) Whole cell lysates were used in immunoblotting with a specific antibody 
that recognizes GLUT1. A representative immunoblot is shown. C) The densitometry of the 
bands expressed in arbitrary units was calculated using Image J software. Protein levels are 
expressed as a comparison of arbitrary units between the MDA-MB-231 and MCF-7 cell line. 
D) Protein levels are expressed as a percentage of the lung fibroblast MRC-5 cell line. Results 
represent the mean ± SEM of three to four independent experiments. 
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86.27, NS) cell line showed a 2.3-fold higher level of GLUT1 protein while the MCF-7 
cell line (25.57  12.39, NS) expressed GLUT1 at a lower level than the lung fibroblast 
line.   
3.1.3 Prostate Cancer Cells 
     GLUT1 mRNA expression was examined in the prostate cancer cell lines 22Rv1, 
LNCaP and PC-3 and expressed as a fold of the noncancerous prostate epithelial cell line 
PNT1A (Figure 15 A). GLUT1 expression was determined to be higher in all prostate 
cancer cell lines than in PNT1A cells. The androgen responsive cell lines 22Rv1 (1.83  
0.42, NS) and LNCaP (2.34  0.68, NS) showed higher GLUT1 mRNA levels while the 
androgen insensitive cell line PC-3 showed an 8.88 fold increase in GLUT1 expression 
(8.88  1.21, p<0.001).  
     Different patterns were observed with respect to protein expression, the 22Rv1 (8.82  
1.07%, p<0.05) cell line was found to express the GLUT1 protein at a lower level than 
the PNT1A cell line and the LNCaP (37.22  16.0%, p=0.077) cell line showed low 
GLUT1 expression compared to PNT1A as well (Figure 15 B). Consistent with the 
mRNA data, PC-3 cells showed higher GLUT1 expression compared to PNT1A cells 
(154.49  26.08%, NS).  
     In order to determine the specificity of the GLUT1 antibody used in western blotting, 
siRNA was used to silence GLUT1 in H1299 cells. Transfection with GLUT1 siRNA 
resulted in down-regulation of a band at 50 kDa suggesting this to be the specific band 
for the protein (Figure s.2 A). 
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3.2 GLUT3 Expression in Cancer Cells  
3.2.1 Lung Cancer Cells  
     GLUT3 mRNA has been reported to be ubiquitously expressed in cells
15
. The H460 
(5.05  0.44, p<0.01) and A549 (2.62  0.18, p<0.05) lung cancer cell lines showed 
higher levels of GLUT3 mRNA compared to the MRC-5 cell line (Figure 16 A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. GLUT1 expression in prostate cancer cells. A) Basal GLUT1 mRNA levels 
were determined by Real Time PCR and are expressed as a fold change of the prostate 
epithelial cell line PNT1A. B) Whole cell lysates were used in immunoblotting with a 
specific antibody that recognizes GLUT1. A representative immunoblot is shown. The 
densitometry of the bands expressed in arbitrary units was calculated using Image J 
software. Protein levels are expressed as a percentage of the PNT1A cell line. Results 
represent the mean ± SEM of three to four independent experiments. (*p<0.05, 
***p<0.001).  
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Figure 16. GLUT3 expression in lung cancer cells. A) Basal GLUT3 mRNA levels were 
determined by Real Time PCR and are expressed as a fold change of the lung fibroblast 
cell line MRC-5. B) Whole cell lysates were used in immunoblotting with a specific 
antibody that recognizes GLUT3. A representative immunoblot is shown. The 
densitometry of the bands expressed in arbitrary units was calculated using Image J 
software. Protein levels are expressed as a percentage of the MRC-5 cell line. Results 
represent the mean ± SEM of three to four independent experiments. (*p<0.05, 
**p<0.01,***p<0.001).  
 
Both SK-MES-1 (0.87  0.38, NS) and H1299 (0.85  0.15, NS) cells expressed GLUT3 
mRNA at a level lower than that found in the MRC-5 cell line.   
     GLUT3 protein was not detected in the MRC-5 cell line, this is consistent with reports 
of GLUT3 expression primarily in the brain and testis
15
 (Figure 16 B). In contrast, 
GLUT3 protein was detected in all of the lung cancer cell lines (Figure 16 B).  The SK-
MES-1 (398.67  58.78%, NS) and A549 (943.47  212.38%, NS) cancer cell lines were  
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found to have the lowest expression of the GLUT3 protein. H460 (2143.71  367.34%, 
p>0.01) cells showed approximately 21-fold higher levels of GLUT3 protein compared to 
MRC-5, and the H1299 (6976.23  600.49%, p>0.001) cell line showed the highest 
expression of GLUT3 at 70-fold higher than the noncancerous lung fibroblast cells.  
3.2.2 Breast Cancer Cells 
     GLUT3 mRNA expression in the MDA-MB-231 breast cancer cell line was similar to 
that found in the noncancerous 184B5 mammary cells (1.05 0.11, NS) (Figure 17 A). 
MCF-7 cells showed minimal GLUT3 mRNA expression that was lower than the levels 
found in the 184B5 cell line (0.001  0.0005, p<0.001). 
     Both breast cancer cell lines displayed GLUT3 expression at the protein level (Figure 
17 B). In contrast to the low GLUT3 mRNA levels in MCF-7 cells, this cell line 
expressed the protein at a similar level to the MDA-MB-231 cell line. When expressed as 
a percentage of the MRC-5 cell line, both the MDA-MB-231 (1690.93  213.31, 
p<0.001) and MCF-7 (1189.86  170.22, p<0.01) breast cancer cell lines showed higher 
expression of the GLUT3 protein.  
3.2.3 Prostate Cancer Cells  
     Expression of GLUT3 mRNA was higher in the 22Rv1 prostate cell line compared to 
the noncancerous PNT1A prostate epithelial cells (9.11  3.01, p<0.05) (Figure 18 A). 
Both the LNCaP (0.029  0.018, NS and PC-3 cell lines showed little expression of 
GLUT3 mRNA (0.0006  0.0002, NS). 
     GLUT3 protein was detected in the PNT1A cell line (Figure 18 B), although this has 
not been reported in previous studies, healthy prostate tissue was shown to express 
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Figure 17. GLUT3 expression in breast cancer cells. A) Basal GLUT3 mRNA levels were 
determined by Real Time PCR and are expressed as a fold change of the mammary 
epithelial cell line 184B5. B) Whole cell lysates were used in immunoblotting with a 
specific antibody that recognizes GLUT3. A representative immunoblot is shown. C) The 
densitometry of the bands expressed in arbitrary units was calculated using Image J 
software. Protein levels are expressed as a comparison of arbitrary units between the MDA-
MB-231 and MCF-7 cell line. D) Protein levels are expressed as a percentage of the lung 
fibroblast MRC-5 cell line. Results represent the mean ± SEM of three to four independent 
experiments.  (**p<0.01,***p<0.001).  
 
GLUT3 through immunohistochemistry
132
. Unlike the high GLUT3 expression that was 
seen at the mRNA level, there was very low detection of the GLUT3 protein in the 
22Rv1 cell line (19.39  9.51%, NS) (Figure 18 B). LNCaP cells were also found to 
express GLUT3 at a lower level than the PNT1A cell line (48.12  20.3%, NS). The PC-3 
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cell line, with low GLUT3 mRNA expression, had the greatest GLUT3 protein 
expression at 1.82-fold higher than that found in PNT1A cells (182.140  45.75%, NS).  
     The specificity of the GLUT3 antibody used was also tested. When siRNA was used 
to silence GLUT3 in H1299 cells this resulted in down-regulation of a band at 45 kDa 
suggesting this to be the specific band for the protein (Figure s.2 B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. GLUT3 expression in prostate cancer cells. A) Basal GLUT3 mRNA levels 
were determined by Real Time PCR and are expressed as a fold change of the prostate 
epithelial cell line PNT1A. B) Whole cell lysates were used in immunoblotting with a 
specific antibody that recognizes GLUT3. A representative immunoblot is shown. The 
densitometry of the bands expressed in arbitrary units was calculated using Image J 
software. Protein levels are expressed as a percentage of the PNT1A cell line. Results 
represent the mean ± SEM of three to four independent experiments. (*p<0.05).  
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3.3 GLUT4 Expression in Cancer Cells  
3.3.1 mRNA Expression 
     GLUT4 mRNA expression is largely restricted to brown and white adipose tissue, 
skeletal and cardiac muscle
15
. GLUT4 mRNA was detected in the MRC-5 lung fibroblast 
cell line and to a lower extent in the H460 lung cancer cell line (0.53  0.038, NS) 
(Figure 19 A). A 3-fold increase in GLUT4 mRNA was seen in the SK-MES-1 (3.25  
0.44, p<0.01), A549 (3.37  0.63, p<0.05) and H1299 (3.51  0.45, p<0.01) lung cancer 
cell lines compared to MRC-5 cells.  
     GLUT4 mRNA was detected in the 184B5 mammary cell line and at similar levels in 
the MDA-MB-231 breast cancer cell line (0.9  0.24, NS) (Figure 19 B). MCF-7 cells 
showed 1.5-fold higher GLUT4 mRNA levels compared to the 184B5 cell line (1.5  
0.56, NS). 
     The 22Rv1 (7.39  2.46, NS) and LNCaP (31.67  4.83, p<0.001) prostate cancer cell 
lines showed markedly higher GLUT4 mRNA expression compared to the noncancerous 
PNT1A prostate epithelial cell line (Figure 19 C). PC-3 cells displayed low GLUT4 
expression at the mRNA level (0.59  0.082, NS).   
3.3.2 Protein Expression  
     There was no detection of the GLUT4 protein using western blotting in both whole 
cell lysates (Figure 20 A) and total membrane fractionations (data not shown) of the  
lung, breast and prostate cancer cell lines and the corresponding noncancerous epithelial 
cell lines. GLUT4 protein was detected in a mouse C2C12 myotube sample (Figure 
20A).  
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Figure 19. GLUT4 mRNA expression in cancer cells. A) Basal GLUT4 mRNA levels 
were determined in lung cancer cell lines by Real Time PCR and are expressed as a fold 
change of the lung fibroblast cell line MRC-5. B) Basal GLUT4 mRNA levels were 
determined in breast cancer cell lines by Real Time PCR and are expressed as a fold 
change of the mammary epithelial cell line 184B5. C) Basal GLUT4 mRNA levels were 
determined in prostate cancer cell lines by Real Time PCR and are expressed as a fold 
change of the prostate epithelial cell line PNT1A. Results represent the mean ± SEM of 
three to four independent experiments. (*p<0.05, **p<0.01,***p<0.001).     
      
     In order to determine if cancer cell lines expressed GLUT4 at the protein level, 
immunofluorescence microscopy was employed as another method of protein detection.   
A549 lung cancer cells and MCF-7 breast cancer cells were found to display cytoplasmic 
GLUT4 staining (Figure 20 B-C). L6 rat skeletal muscle cells were examined as a  
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Figure 20. GLUT4 protein expression in cancer cells. A) Whole cell lysates were used in 
immunoblotting with a specific antibody that recognizes GLUT4. This protein was not 
detected in the human cancer cell lines, however the antibody recognized GLUT4 in a 
C2C12 mouse skeletal muscle sample.  A representative immunoblot is shown. A549 (B), 
MCF-7 (C) and L6 rat myotube cells (D) were immunostained with GLUT4 and images 
were obtained from a widefield fluorescent microscope. A representative section from 
each sample is shown. Results are representative of two independent experiments.    
 
positive control and found to also display strong cytoplasmic GLUT4 staining (Figure 20 
D).  
 
3.4 GLUT12 Expression in Cancer Cells  
3.4.1 mRNA Expression  
     GLUT12 mRNA expression is found in insulin-sensitive tissues as well as the small 
intestine, prostate and placenta and mammary gland
41,42
. The SK-MES-1 lung cancer cell 
line showed higher levels of GLUT12 mRNA compared to the MRC-5 cell line (3.22  
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1.26, NS) (Figure 21 A). The H460 (0.124  0.05, NS), A549 (0.44  0.13, NS) and 
H1299 (0.002  0.001, NS) cell lines were found to express low GLUT12 mRNA levels 
compared to MRC-5 cells.  
      In comparison to the 184B5 cell line, MDA-MB-231 (3.42  0.26, p<0.001) breast 
cancer cells showed 3-fold higher levels of GLUT12 mRNA expression (Figure 21 B). 
The GLUT12 transporter was first described in MCF-7 breast cancer cells, consistent 
with these reports GLUT12 mRNA was detected in the MCF-7 (0.07  0.006, p<0.05) 
cell line, however, this was at lower levels than in the 184B5 cell line.  
     Within the prostate cancer cell lines, 22Rv1 (0.16  0.065, NS) cells expressed lower 
GLUT12 mRNA levels than the PNT1A epithelial cell line (Figure 21 C). Both the 
LNCaP (8.58  2.88, p<0.05) and PC-3 (2.47  0.68, NS) cell lines showed higher 
GLUT12 mRNA expression at approximately 8- and 2-fold higher than the noncancerous 
PNT1A cells, respectively.  
 
3.5 GLUT Expression in Xenograft Tumours  
     In order to determine the in vivo expression of GLUT proteins, tumours from Balb/c 
nude mice xenografted with H1299, A549 and PC-3 human cancer cells were 
immunohistochemically examined for the presence of GLUT1 and GLUT3. Faint 
cytoplasmic and discontinuous membrane staining of GLUT1 was observed in the H1299 
tumours (Figure 22 A). This staining appeared to be stronger in the A549 and PC 
tumours (Figure 22 B-C). GLUT3 staining was detected in all three tumour types 
(Figure 23 A-C). The H1299 and A549 tumours showed signs of both faint cytoplasmic 
and discontinuous membrane staining (Figure 23 A-B) while the GLUT3 protein in the  
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Figure 21. GLUT12 mRNA expression in cancer cells. A) Basal GLUT12 mRNA levels 
were determined in lung cancer cell lines by Real Time PCR and are expressed as a fold 
change of the lung fibroblast cell line MRC-5. B) Basal GLUT12 mRNA levels were 
determined in breast cancer cell lines by Real Time PCR and are expressed as a fold 
change of the mammary epithelial cell line 184B5. C) Basal GLUT12 mRNA levels were 
determined in prostate cancer cell lines by Real Time PCR and are expressed as a fold 
change of the prostate epithelial cell line PNT1A. Results represent the mean ± SEM of 
three to four independent experiments. (*p<0.05,***p<0.001).     
 
PC-3 tumours appeared to be mainly cytoplasmic (Figure 23 C). There was no signal 
detected in the slides that were not incubated in primary antibody as a control (Figures 
s.3-4). The specificity of immunohistochemistry staining was confirmed by a clinically 
trained pathologist. 
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Figure 22. GLUT1 expression in tumours from nude mice xenografted with cancer cell lines. Paraffin-
embedded sections of H1299 (A), A549 (B) and PC-3 (C) tumours were incubated with anti-GLUT1 
antibody and analyzed by immunohistochemistry . Representative images of three independent experiments 
are shown. Magnification=18.4X   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. GLUT3 expression in tumours from nude mice xenografted with cancer cell lines. Paraffin-
embedded sections of H1299 (A), A549 (B) and PC-3 (C) tumours were incubated with anti-GLUT3 
antibody and analyzed by immunohistochemistry. Representative images of three independent experiments 
are shown. Magnification=18.4X 
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Table. 7 Summary of GLUT Expression in Cancer Cell Lines by Mutation Status 
Mutation status  Cell Lines  mRNA Expression*   Protein Expression**  
p53 null SK-MES-1  
(Lung squamous cell 
carcinoma) 
GLUT1 (p<0.01) 
 GLUT3 
 GLUT4 (p<0.01) 
 GLUT12 
GLUT1 (p<0.01) 
GLUT3 
H1299 
(Lung 
adenocarcinoma) 
GLUT1 
GLUT3 
GLUT4 (p<0.01) 
GLUT12 
GLUT1 (p<0.05) 
GLUT3 (p<0.001) 
MDA-MB-231 
(Breast 
adenocarcinoma) 
GLUT1 
GLUT3  
GLUT4  
GLUT12 (p<0.001) 
GLUT1 
GLUT3 
22Rv1 
(Prostate 
adenocarcinoma) 
GLUT1 
GLUT3 (p<0.05) 
GLUT4 
GLUT12 
GLUT1 (p<0.05) 
GLUT3 
PC-3 
(Prostate 
adenocarcinoma) 
GLUT1 (p<0.001) 
GLUT3 
GLUT4 
GLUT12 
GLUT1 
GLUT3 
KRAS mutant H460 
(Lung large cell 
carcinoma) 
GLUT1 
 GLUT3 (p<0.01) 
GLUT4 
 GLUT12 
GLUT1 
GLUT3 (p<0.01) 
A549 
(Lung 
adenocarcinoma) 
GLUT1 
GLUT3 (p<0.05) 
GLUT4 (p<0.05) 
GLUT12 
GLUT1 
GLUT4 
MDA-MB-231 
(Breast 
adenocarcinoma) 
GLUT1 
GLUT3  
GLUT4  
GLUT12 (p<0.001) 
GLUT1 
GLUT3 
PIK3CA 
mutant 
H460 
(Lung large cell 
carcinoma) 
GLUT1 
 GLUT3 (p<0.01) 
GLUT4 
 GLUT12 
GLUT1 
GLUT3 (p<0.01) 
MCF-7 
(Breast 
adenocarcinoma) 
GLUT1 
GLUT3 (p<0.001) 
GLUT4  
GLUT12 (p<0.05) 
GLUT1 
GLUT3  
GLUT4 
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PTEN null LNCaP 
(Prostate 
adenocarcinoma) 
GLUT1  
GLUT3  
GLUT4 (p<0.001) 
GLUT12 (p<0.05) 
GLUT1 
GLUT3 
PC-3 
(Prostate 
adenocarcinoma) 
GLUT1 (p<0.001) 
GLUT3 
GLUT4 
GLUT12 
GLUT1 
GLUT3 
*If no p value provided, the GLUT mRNA was detected in the cell line but not significantly different than 
the corresponding noncancerous cell line  
** If no p value provided, the GLUT protein was detected in the cell line but not significantly different than 
the corresponding noncancerous cell line 
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CHAPTER 4: DISCUSSION 
     Given that cancer cells display an increased rate of glucose uptake and consumption 
compared to healthy cells, it is important to understand the role of glucose transporter 
proteins in cancer cell metabolism. Although previous studies have suggested that 
GLUTs are over expressed in cancer, GLUT expression in a number of cell lines, with 
different mutations and histologies, has not been characterized. The current study 
revealed a number of new findings regarding GLUT detection in cancer cell lines and 
confirmed the findings of previously reported GLUT expression. 
 
4.1 GLUT1 Expression in Cancer Cells  
     In support of previous research that has highlighted an important role of GLUT1 in the 
increased glucose uptake by cancer cells
16,70,132
,
 
GLUT1 was found to be the most highly 
expressed GLUT at the mRNA level in six out of the nine cancer cell lines studied 
(Figures s.9-11).  In comparison to the MRC-5 lung fibroblast line, higher GLUT1 
expression was observed at the mRNA and protein level in SK-MES lung cancer cells 
and at the protein level in the H1299 cell line (Figure 13). This is consistent with 
previous reports of elevated GLUT1 expression in primary lung tumours as compared to 
normal lung tissue
168-170
. Suzawa et al. (2011) found a higher degree of GLUT1 protein 
overexpression in squamous cell carcinomas than adenocarinomas
171
. While the SK-MES 
squamous lung cancer cell line in this study had significantly increased GLUT1 mRNA 
and protein levels, the A549 adenocarcinoma cell line had comparatively lower 
expression and the H1299 adenocarcinoma showed significant GLUT1 overexpression 
only at the protein level. Therefore, some types of lung adenocarcinomas may have a 
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greater degree of GLUT1 upregulation than others. Indeed, a study by Rastogi et al. also 
demonstrated higher GLUT1 expression in the H1299 cell line than in A549 cells
164
. 
Elevated GLUT1 levels are also apparent in large cell lung cancer as the H460 cell line 
showed increased mRNA and protein levels compared to MRC-5 cells, this is supported 
by a study showing higher GLUT1 mRNA expression in the H460 cell line as compared 
to a control cell pool
128
. Therefore, GLUT1 overexpression was detected in all types of 
lung cancer studied suggesting this transporter may play an important role in providing 
nutrients to lung cancers.  
     Despite the lack of GLUT1 detection in breast cancer tumours in previous studies
129-
131
, both breast cancer cell lines investigated were found to express GLUT1 at the mRNA 
and protein level (Figure 15). The more aggressive estrogen-independent breast cancer 
cell line MDA-MB-231 was found to express greater GLUT1 mRNA and protein than the 
estrogen receptor positive cell line MCF-7. This was also noted in the study by Grover-
McKay et al. 1998 in which cell surface GLUT1 expression was found to be associated 
with the invasive ability of the breast cancer cell lines studied
172
. This suggests GLUT1 
expression may be useful in identifying more aggressive and invasive types of breast 
cancer.    
     The present study provides the first comparison of glucose transporter expression 
between a noncancerous prostate epithelial cell line and various cancer cell lines. The 
finding that GLUT1 mRNA expression was elevated in all of the prostate cancer cell 
lines compared to PNT1A suggests that upregulation of this transporter may be 
characteristic of cancerous prostate cells (Figure 16). These findings are in accordance 
with previous reports of GLUT1 mRNA detection in LNCaP and PC-3 cells
139,142
. While 
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studies of malignant prostate tissue have been negative for GLUT1
139-141
, here the protein 
was detected at variable levels in all of the cancer cell lines. Interestingly, GLUT1 
expression at the mRNA and protein level was highest in the androgen-insensitive line 
PC-3 compared to the other cell lines that are better differentiated. This is supported by 
Effert et al. (2004) who also found higher GLUT1 mRNA expression in the PC-3 cell line 
than LNCaP cells
142
. In derivatives of LNCaP cells, however, no relationship was found 
between tumour progression and the level of GLUT1 expression
139
. Therefore, more 
work is needed to clarify if GLUT1 expression increases with the degree of prostate 
cancer malignancy.  
 
4.2 GLUT3 Expression in Cancer Cells  
     Several studies have reported GLUT3 protein expression in lung cancer 
tumours
140,170,171,173
. Unlike the results of Suzawa et al. (2011) that showed a significantly 
higher expression of GLUT3 in lung squamous cell carcinomas than adenocarcinomas, in 
this study the SK-MES cell line was found to have lower mRNA and protein expression 
of this transporter compared to the adenocarcinoma cell lines (Figure 17). Evidence for 
use of GLUT3 as an indicator of cancer can be seen by the absence of the GLUT3 protein 
in the noncancerous MRC-5 cell line and its consistent expression in the lung cancer cell 
lines. The differences in GLUT3 protein between MRC-5 cells and H460 and H1299 cell 
lines were striking at 21-fold or 70-fold higher, respectively. Interestingly, the H1299 cell 
line was shown to possess more GLUT3 than GLUT1 mRNA (Figure s.9), suggesting an 
important role of this transporter in the cell line. The limited data available regarding 
GLUT3 expression in lung cancer cell lines supports the finding of significantly elevated 
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GLUT3 mRNA in the H460 and A549 cell lines as Cao et al. (2007) reported a 1.5-1.7 
fold mRNA increase in H460 cells compared to a control cell pool and increased 
expression in A549 cells
128
.  
     Fewer studies have examined GLUT3 expression in breast cancer tumours. The 
reports consist of low levels of expression in these tumours or a failure to detect the 
protein
136,140,154
. In contrast, this study detected GLUT3 at the protein level in both breast 
cancer cell lines investigated (Figure 18 B). In support of these results, Grover-McKay et 
al. (1998) also found GLUT3 protein to be present in the MDA-MB-231 and MCF-7 cell 
lines
172
. Although this group did not observe a correlation between GLUT3 expression 
and cell line invasiveness, Krzeslak et al. (2012) found a significantly higher expression 
in poorly differentiated tumours
136
. Protein expression between the MDA-MB-231 and 
MCF-7 cell lines was found to be similar in this study suggesting potential differences in 
GLUT3 regulation between breast cancer cells in vitro and in vivo.  
     The present study is the first to report mRNA and protein expression of GLUT3 in 
prostate cancer cell lines. Discrepancies between the mRNA and protein data were 
apparent, as the 22Rv1 cell line had significantly elevated GLUT3 mRNA and negligible 
protein expression and the PC-3 cell line showed elevated protein, but not mRNA, 
expression (Figure 19). GLUT3 does not appear to be consistently overexpressed in 
different types of prostate cancer.  
 
4.3 GLUT4 Expression in Cancer Cells  
     A growing body of evidence links circulating insulin levels to the development of 
cancer
174
. In order to better understand the relationship between insulin and cancer 
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progression, the expression of the insulin-sensitive glucose transporter GLUT4 must be 
established in various cancers to determine if the metabolism of these cells may include 
insulin-mediated glucose uptake. Although GLUT4 has been sporadically detected in 
lung cancer tissue
140,152
, previous studies have not determined the expression of this 
transporter in cancer cell lines. A number of cell lines displayed increased mRNA 
expression of GLUT4 in this study. In the lung cancer cell lines, both A549 and H1299 
adenocarcinoma cell lines and the squamous cell line SK-MES had approximately 3-fold 
higher expression of GLUT4 (Figure 20 A). As well, the 22Rv1 and LNCaP prostate 
cancer cell lines had 7- and 31-fold increases in GLUT4 mRNA compared to the 
noncancerous prostate cell line, respectively. The upregulation of this gene in a number 
of cancer types suggests tissues that are typically not considered insulin-sensitive may 
express this transporter when they become malignant. The GLUT4 protein was not 
detected through western blotting in any of the cell lines (Figure 21 A), this is likely due 
to the nature of this technique and the difficulty of the antibody recognizing the linear 
form of the epitope of the protein. Immunofluorescence microscopy showed cytoplasmic 
staining of GLUT4 in both A549 and MCF-7 cells indicating that GLUT4 is also present 
at the protein level in these cells. Although GLUT4 protein expression in the remaining 
cell lines was not determined, this is an interesting finding and the phenomenon of 
GLUT4 expression at the mRNA and protein level in tissues that are not known to be 
insulin sensitive should be further investigated. The role of growth factors in 
carcinogenesis is well established but the influence of growth factors on GLUT 
expression and activity in cancer cells is less clear. Whether growth factors influence 
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proliferation of cancer cells through upregulation and translocation of GLUTs remains to 
be examined.  
 
4.4 GLUT12 Expression in Cancer Cells  
     The GLUT12 transporter was first identified and cloned in the MCF-7 breast cancer 
cell line and has subsequently been shown to be expressed more strongly in breast 
carcinoma than benign tissue
41,42
. To date, few studies have examined the expression of 
GLUT12 in cancer tissues and cell lines. The results of the current study reveal increased 
mRNA expression of GLUT12 in select cancer cell lines, those being SK-MES, MDA-
MB-231, LNCaP and PC-3 (Figure 22). Consistent with the reports of Rogers et al. 
(2002) GLUT12 mRNA was detected in the MCF-7 cell line
41
. Given that previous 
findings have shown GLUT12 protein expression to be increased in response to estrogen, 
it is interesting that the estrogen receptor negative MDA-MB-231 breast cancer cell line 
showed a marked increase in GLUT12 mRNA expression. The protein expression of this 
transporter was not determined in this study due to the lack of a commercially reliable 
GLUT12 antibody. In the study by Macheda et al. (2005)
16
, GLUT12 protein was not 
detected in the MDA-MB-231 cell line, suggesting that while breast cancer cells show 
increased mRNA expression of GLUT compared to healthy breast cells, translation of 
this mRNA may be dependent on sex hormones. This has implications for therapeutic 
treatment as hormone therapies for cancers may modulate glucose uptake by GLUT12. 
The androgen sensitive LNCaP cell line had the highest GLUT12 mRNA expression over 
its corresponding noncancerous cell line with an 8-fold increase over PNT1A. The study 
by Chandler et al. (2003) also examined GLUT12 expression in this cell line and found it 
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to be detected at the mRNA and protein level
107
. The protein expression of GLUT12 in 
these cells lines, and the correlation between mRNA and protein levels, is an important 
issue to address in future research.   
 
4.5 Discrepancies between GLUT mRNA and Protein Expression  
 
     Although the mRNA and protein expression of the glucose transporters were 
associated in most instances, there are some cell lines in which discrepancies exist. Many 
studies have found the correlation between mRNA and protein expression to be weak
175, 
176
. The most recent large scale study of more than 5,000 mammalian genes by 
Schwanhausser et al. (2011) suggests that approximately 40% of the variance in protein 
levels can be explained by mRNA levels
177
. This study found that protein levels are best 
predicted by translation efficiency rather than transcription rates. Thus, in cell lines that 
showed abundant mRNA expression of a specific transporter, regulation of translation 
may have prevented the mRNA from ever being translated into protein resulting in low or 
absent protein expression. In the case of GLUT3 it is known that in most tissues mRNA 
is expressed but not translated into protein
178
, therefore it is possible this also occurs with 
other glucose transporters in cancer. In cell lines that show relatively low GLUT mRNA 
expression with high protein levels (ie. H1299) with respect to GLUT1 and GLUT3 
(Figures 14 and 17), high translation rates may account for this discrepancy. 
Schwanhausser’s study found that proteins are approximately 900 times more abundant 
than corresponding transcripts, therefore small changes in mRNA expression may result 
in significant differences at the protein level.  
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4.6 The Cell Culture Environment  
 
     Although there are a number of advantages to using a cell culture model to determine 
expression patterns in cancer, there are certain limitations that should be considered when 
interpreting results. Cells grown in vitro have an unlimited supply of nutrients and 
oxygen, both of which have been shown to affect glucose transporter expression. Cell 
culture studies have shown that GLUT1 expression is higher in cells that are deprived of 
glucose
179
, and hypoxia, which frequently occurs in solid tumours, has been shown to 
upregulate the expression of GLUT1 and GLUT3
85
. Therefore, the degree of GLUT 
expression in cancer may be underestimated in this study compared to tumours in which 
inadequate blood supply, and a lack of glucose and oxygen, would be common.  
 
4.7 GLUT Expression In Vivo 
 
     Despite the potential limitations of using a cell culture model, in vivo data supported 
the findings of the present study regarding GLUT protein expression in vitro. The 
expression of GLUT1 and GLUT3 in tumours from nude mice xenografted with H1299, 
A549 and PC-3 cancer cells demonstrated that glucose transporter expression in cancer 
cell lines is not a phenomenon only seen in cell culture. The GLUT1 protein was found to 
be localized to the cytoplasm and the plasma membrane in the lung and prostate tumours. 
The discontinuous membrane staining observed is likely due to areas of hypoxia and 
differing vascularization within the tumour. Future examination of hypoxia and 
angiogenesis markers in these samples would provide a clearer understanding of glucose 
transporter expression patterns in tumours. In contrast to the western blotting results of 
the lung cancer cell lines, the lowest GLUT1 expression appeared in the H1299 tumours, 
It is possible other glucose transporters play a more prominent role for these cancer cells 
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in vivo. Indeed, H1299 tumours had roughly equal expression of GLUT1 and GLUT3. 
This protein was also detected in the cytoplasm and plasma membrane of the cancer cells. 
A549 and PC-3 tumours appeared to have a lower extent of GLUT3 expression compared 
to GLUT1, this is supported by the mRNA data for these cell lines (Figures s.9 D and 
s.11 D). Few studies have looked at GLUT expression in xenograft models and based on 
findings from this research, this may be a useful model for studying GLUT proteins.  
 
4.8 Additional Nutrients Used by Cancer Cells  
     The GLUT family has an ability to transport substrates other than glucose, therefore, it 
is possible overexpression of GLUTs in cancer may be due to increased needs for other 
sugars. For example, GLUT1 transports glucose as well as galactose, mannose, 
glucosamine and dehydroascorbic acid (Table 1). The glucose uptake of the cancer cell 
lines in this study was not measured, therefore it cannot be determined whether an 
increase in the expression of specific GLUTs correlates with an increase in glucose 
uptake. The findings of elevated GLUT expression in cancers that have high FDG-PET 
accumulation suggests a similar relationship may be seen in cancer cell lines, however 
this should be addressed in future research.  
     There is evidence that tumours have increased demands for nutrients other than 
glucose. Cancer cells appear to take up high levels of essential and non-essential amino 
acids, specifically the amino acid glutamine
180
. In addition, changes in fatty acid 
metabolism have been observed in some cancers. It has been demonstrated that fatty acid 
uptake is dominant over glucose uptake in the prostate cancer cell lines LNCaP and PC-
3
181
. Furthermore, FDG-PET has been shown to have limited accuracy in the diagnosis 
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and staging of prostate cancer, indicating glucose uptake may not be more important for 
prostate cancer than healthy tissue
182
. In this study, significant differences in GLUT 
expression were found between the prostate cancer cell lines and the noncancerous 
PNT1A cell line and high GLUT levels were also seen in a comparison with the lung and 
breast cancer cell lines (Figures s.4-7). Given the limited clinical applicability of FDG-
PET in prostate cancer it is unclear why GLUTs are upregulated in prostate cancer cell 
lines. Whether the expressed glucose transporters may be used to transport other hexoses, 
or whether they have limited transport activity, remains to be examined.  
 
4.9 Mutation Status and Expression of GLUTs 
 
     Given what is known about the potential oncogenic regulation of GLUTs and 
suppression of these transporter genes by tumour suppressors, it is expected that cell lines 
with the same mutation status will show similar patterns of GLUT expression. The 
tumour suppressor p53 has been previously reported to downregulate the expression of 
GLUT1, GLUT3, GLUT4 and GLUT12
81,90,105
. In the cancer cell lines examined, those 
harbouring a mutation in p53 (SK-MES, H1299, MDA-MB-231 and PC-3) were shown 
to overexpress GLUT1 in comparison to the corresponding noncancerous cell line of that 
tissue.  
     The regulation of GLUTs appears to be complex, not all cancer cell lines with p53 
mutations had upregulation of the same GLUTs and those with elevated mRNA levels 
did not always show the same pattern at the protein level. This was seen in the 22Rv1 cell 
line that had significantly increased GLUT3 mRNA levels without a subsequent increase 
in protein expression. It is possible that while loss of p53 function can relieve the 
inhibitory effects on GLUT3 transcription, there are other factors influencing whether 
Investigation of the Expression of Glucose Transporter Proteins in Human Cancer Cells 92 
translation of this mRNA will occur. Likewise, GLUT12 mRNA expression was seen in 
two of the p53 mutant cell lines studied, the SK-MES and MDA-MB-231 cell lines, and 
Macheda et al. (2005) have previously shown that MDA-MB-231 cells do not express the 
GLUT12 protein
16
.  
     In support of the evidence implicating an inhibitory effect of p53 on the transcriptional 
activity of GLUT4, significant increases in GLUT4 mRNA expression were seen in the 
p53 mutant cell lines SK-MES and H1299, and the 22Rv1 cell line showed a 7-fold 
increase in mRNA expression. In this study the expression of GLUT4 protein in these 
cell lines was not measured, however, this remains an important issue to address to 
determine if pharmacological reactivation of p53 may be useful for preventing the growth 
of these cancer cells. 
     Both mutations in the PIK3CA gene and the tumour suppressor PTEN lead to the 
kinase Akt being constitutively activated. Akt has been shown to increase expression of 
both GLUT1 and GLUT3 and translocation of GLUT4
46-48
.  In the H460 cell line, which 
harbours a PIK3CA mutation, GLUT1 and GLUT3 were increased at both the mRNA 
and protein level. In comparison, the MCF-7 cell line showed elevated GLUT1 mRNA 
and GLUT3 protein. Similar effects on the expression of GLUT1 and GLUT3 would 
therefore be expected in the PTEN mutant cell lines LNCaP and PC-3. Interestingly, 
these cell lines both show increased GLUT12 mRNA levels and GLUT4 mRNA 
expression was significantly elevated in the LNCaP line. Whether GLUT12 and GLUT4 
gene expression is also suppressed by PTEN is worthy of investigating, it is possible that 
tumour suppressors play an important role in down-regulating GLUT expression in 
healthy tissue.  
Investigation of the Expression of Glucose Transporter Proteins in Human Cancer Cells 93 
     Additionally, cancer cells with K-ras mutations have been shown to have elevated 
glucose uptake and upregulation of GLUT1 mRNA
80
. Of the three Kras mutant cell lines 
studied, increased GLUT1 mRNA and protein levels were observed in the H460 and 
MDA-MB-231 cell lines. The breast cancer MDA-MB-231 cell line had the highest 
GLUT1 mRNA expression of all cancer cell lines studied (Figure s.5) suggesting that the 
presence of both p53 and K-ras mutations in this cell line may lead to substantial 
upregulation of this transporter. An increase in GLUT3 mRNA was seen in the K-ras 
mutant lung cancer cell lines A549 and H460, with a significant increase in GLUT3 
protein in the H460 cell line. The potential regulation of GLUT3 by K-ras mutations in 
cancer should be further explored.  
     Another mutation that may be relevant to the GLUT expression observed in cancer 
cells studied is loss of the tumor suppressor LKB1. This protein was originally identified 
as a tumor suppressor in humans because it is mutated in Peutz-Jeghers syndrome (PJS). 
Subjects with PJS develop benign tumors in the gastrointestinal tract and have an 
increased risk of developing malignant tumors at other sites
91
. The LKB1 protein is the 
major upstream kinase responsible for regulating AMPK
91
. Given that AMPK is involved 
in regulation of the transcription and localization of several GLUTs, loss of LKB1 may 
lead to deregulation of GLUT expression in cancer. The lung cancer cell lines A549 and 
H460 lack functional LKB1 and show high levels of GLUT3 at the mRNA and protein 
level. Although AMPK has been demonstrated to cause translocation of GLUT3 to the 
plasma membrane and increase its activity
92,93
, its role in regulating this transporter in 
lung cancer cells is unclear. Whether the elevated expression of GLUT3 in these cell 
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lines is due to decreased AMPK activation because of the loss of LKB1 remains to be 
examined.  
     The regulation of multiple GLUTs by the same mutations and pathways may explain 
the redundancy that is seen in some cancer cell lines where high expression levels of 
more than one GLUT is seen. Studies determining whether all of the glucose transporters 
expressed in the cancer cell line are active in taking up glucose, and if this happens 
simultaneously or if some GLUTs are preferred under certain conditions, will aid in our 
understanding of the potential role of GLUT proteins in cancer growth and survival.   
 
4.10 Significance of the Present Study 
     Previous research has indicated that expression of certain GLUTs may be upregulated 
in cancer. While the majority of these studies have used tumour models, the present study 
examined GLUT expression in vitro using a number of cancer cell lines with different 
mutations and histologies. Additionally, this study included the comparison of a 
noncancerous cell line of the corresponding tissue type in order to determine GLUT 
expression patterns that were specific to cancer cell lines.  
     The findings of this study can serve as a reference for authors wishing to select an 
appropriate in vitro model to study GLUT1, GLUT3, GLUT4 or GLUT12. It also 
provides evidence that GLUTs are expressed in the cell lines studied both in vitro and in 
vivo as expression of GLUT1 and GLUT3 were detected in xenografts grown in 
immunodeficient mice. The results presented provide a baseline for further investigation 
of GLUTs as biomarkers of cancer progression and potential targets for therapeutics.  
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4.11 Future Directions  
 
     Recent attempts to inhibit GLUT-mediated glucose uptake in cancer cells have 
focused on GLUT1. The present study suggests that GLUT3, GLUT4 and GLUT12 may 
also serve as potential candidates for targeting in cancer. Once the expression of the 
glucose transporters within a specific cancer/tumour has been established, future research 
should focus on determining the activity of these transporters and whether they play a 
functional role in providing energy and nutrients to the cancer cell. This will provide 
stronger evidence to target GLUTs for anti-cancer therapy than expression patterns alone.  
   Additional studies are required to better understand the complex regulation of GLUTs 
and to explain the discrepancies observed in this study between mRNA and protein 
expression of some GLUTs. The relationship between tumour suppressor genes and the 
regulation of GLUTs should be explored in detail to determine if p53 inhibits aerobic 
glycolysis by downregulating the expression of multiple GLUTs and if PTEN may play a 
similar role.  
     The potential modulation of GLUT expression by current cancer therapeutics has not 
been studied and should be investigated to better understand how these therapies affect 
cancer cell metabolism. Using agents that decrease GLUT translocation and/or 
expression while also acting on pathways to inhibit proliferation may represent attractive 
strategies for the treatment of cancer. Furthermore, GLUTs could serve as biomarkers of 
tumour response to these agents.  
    Expression patterns of additional members of the GLUT family should be examined in 
cancer cell lines and tumour samples. Potential GLUTs of interest may include the 
fructose transporters GLUT2, GLUT5, GLUT7 and GLUT11 since increased rates of 
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fructose uptake have been observed in some cancers
183,184
 and GLUT8 as this transporter 
has been suggested to be important during development
185  
and has recently been 
described in multiple myeloma and endometrial cancers
186,187
.  
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CHAPTER 5: CONCLUSIONS 
1) The present study examined the expression of the glucose transporters 
GLUT1, GLUT3, GLUT4 and GLUT12 at the mRNA level in lung, breast 
and prostate cancer cell lines as well as the corresponding non-cancerous cell 
lines of that tissue. SK-MES-1 lung cancer cells and PC-3 prostate cancer 
cells were found to have higher GLUT1 mRNA expression than non-
cancerous cells of that tissue. H460 and A549 lung cancer cells, and 22Rv1 
prostate cancer cells had high levels of GLUT3 mRNA, while in MCF-7 
breast cancer cells the levels were lower than that found in non-cancerous 
cells.  High GLUT4 mRNA expression was found in SK-MES-1, A549 and 
H1299 lung cancer, and LNCaP prostate cancer cells. The MDA-MB-231 
breast and LNCaP prostate cancer cell lines were found to have high levels of 
GLUT12 mRNA compared to non-cancerous cells.  
2) Next, the present examined the protein expression of GLUT1, GLUT3, 
GLUT4 and GLUT12 in the aforementioned cancer cell lines. SK-MES-1 and 
H1299 lung cancer cells were found to have higher GLUT1 protein expression 
than non-cancerous lung fibroblast cells, while 22Rv1 prostate cancer cells 
expressed GLUT1 at lower levels than non-cancerous prostate epithelial cells. 
The lung cancer cells H460 and H1299, and the breast cancer cells MDA-MB-
231 and MCF-7 had higher GLUT3 protein expression compared to the lung 
fibroblast cell line MRC-5. GLUT4 protein was not recognized in human 
cancer cell lines using western blotting, however, when selecting the cancer 
cell lines A549 and MCF-7 for use in immunofluorescence microscopy, 
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GLUT4 protein was detected in the cytoplasm of these cells. GLUT12 protein 
expression was not examined due to the unavailability of a specific antibody.  
3) In order to determine the in vivo expression of GLUTs in cancer cells, 
expression of GLUT1 and GLUT3 was examined in tumours from nude mice 
xenografted with cancer cell lines. In agreement with the expression of 
GLUT1 and GLUT3 protein observed in tissue culture models of H1299, 
A549 and PC-3 cells, both transporters were also detected in tumour 
xenografts of these cells lines.  
     In summary, the present study revealed new findings of GLUT detection in cancer 
cells and describes basal GLUT expression patterns in a number of cancer cells with 
different mutations and histologies. The study of GLUT protein expression in cancer is 
important for understanding cancer metabolism and may lead to identification of 
biomarkers of cancer progression and development of target therapies. 
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APPENDIX 
 
Supplemental Figures 
 
Figure s.1. Efficiency testing of GLUT1 primer. A) Amplification of cDNA synthesized from different amounts of 
RNA. Serial dilutions of cDNA were amplified by real-time PCR to determine the efficiency of amplification of the 
GLUT1 gene and internal control (RPII-2). The Ct values at each cDNA dilution were plotted for each gene and 
slope of the line was determined to be similar, indicating that the GLUT1 primer has a similar efficiency to the 
reference gene primer and the 2
-[Δ][Δ]Ct
 calculation for the relative quantification of target may be used. B) The 
differences between the Ct value of GLUT1 and RPII-2 were plotted against the log of the concentration of cDNA 
samples. A delta Ct slope of less than 0.1 indicates similar efficiencies of the target and reference genes, therefore, 
since the delta Ct slope was determined to be 0.0645 it can be inferred that the GLUT1 and RPII-2 primers have 
similar efficiencies. C) The amplified PCR product collected when using the GLUT1 primer was run on an agarose 
gel and a strong band appeared under the 200 bp standard marker. This is consistent with the expected size of the 
product of 189 bp. 
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Figure s.2. siRNA knockdown of GLUT1 and GLUT3 in H1299 cells. H1299 cells were incubated with 
transfection reagent (TR) or transfection reagent + GLUT1 (A) or GLUT3 (B) siRNA to transiently knock 
down these transporters. The specificity of the GLUT antibodies was examined by immunoblotting with 
whole cell lysates from each group.    
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure s.3. Immunohistochemistry analysis of no-primary GLUT1 controls. Parrafin-embedded sections of 
H1299 (A), A549 (B) and PC-3 (C) tumours were not incubated with an anti-GLUT1 antibody and then 
analyzed by immunohistochemistry . No signal was detected in these tumours. Representative images of 
three independent experiments are shown. Magnification=18.4X 
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Figure s.4. Immunohistochemistry analysis of no-primary GLUT3 controls. Parrafin-embedded sections of 
H1299 (A), A549 (B) and PC-3 (C) tumours were not incubated with an anti-GLUT3 antibody and then 
analyzed by immunohistochemistry . No signal was detected in these tumours. Representative images of 
three independent experiments are shown. Magnification=18.4X 
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Figure s.5. GLUT1 mRNA expression in cancer cell lines normalized to MRC-5. Basal GLUT1 mRNA 
levels were determined in lung, breast and prostate cancer cell lines by Real Time PCR and expressed as a 
fold change of the lung fibroblast cell line MRC-5. Results represent the mean ± SEM of three to four 
independent experiments. 
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Figure s.6. GLUT3 mRNA expression in cancer cell lines normalized to MRC-5. Basal GLUT3 mRNA 
levels were determined in lung, breast and prostate cancer cell lines by Real Time PCR and expressed as a 
fold change of the lung fibroblast cell line MRC-5. Results represent the mean ± SEM of three to four 
independent experiments.  
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Figure s.7. GLUT4 mRNA expression in cancer cell lines normalized to MRC-5. Basal GLUT4 mRNA 
levels were determined in lung, breast and prostate cancer cell lines by Real Time PCR and expressed as a 
fold change of the lung fibroblast cell line MRC-5. Results represent the mean ± SEM of three to four 
independent experiments.  
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Figure s.8. GLUT12 mRNA expression in cancer cell lines normalized to MRC-5. Basal GLUT12 mRNA 
levels were determined in lung, breast and prostate cancer cell lines by Real Time PCR and expressed as a 
fold change of the lung fibroblast cell line MRC-5. Results represent the mean ± SEM of three to four 
independent experiments.  
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Figure s.9. GLUT expression within each lung cell line normalized to the lowest expressed GLUT. A) 
GLUT expression in the MRC-5 cell line normalized to GLUT4. B) GLUT expression in the SK-MES-1 
cell line normalized to GLUT4. C) GLUT expression in the H460 cell line normalized to GLUT4. D) 
GLUT expression in the A549 cell line normalized to GLUT4. E) GLUT expression in the H1299 cell line 
normalized to GLUT12.  
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Figure s.10. GLUT expression within each breast cell line normalized to the lowest expressed GLUT. A) 
GLUT expression in the 184B5 cell line normalized to GLUT4. B) GLUT expression in the MDA-MB-231 
cell line normalized to GLUT4. C) GLUT expression in the MCF-7 cell line normalized to GLUT3.   
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Figure s.11. GLUT expression within each prostate cell line normalized to the lowest expressed GLUT. A) 
GLUT expression in the PNT1A cell line normalized to GLUT4. B) GLUT expression in the 22Rv1 cell 
line normalized to GLUT12. C) GLUT expression in the LNCaP cell line normalized to GLUT3.  D) 
GLUT expression in the PC-3 cell line normalized to GLUT3.  
 
 
 
 
 
 
